Stockwinners Market Radar for May 03, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:49 EDT Aerojet Rocketdyne reports Q1 backlog $6.4B - Aerojet Rocketdyne states: "As of March 31, 2022, the Company's total remaining performance obligations, also referred to as backlog, totaled $6.4B. The Company expects to recognize approximately 37%, or $2.4B, of the remaining performance obligations as sales over the next twelve months, an additional 26% the following twelve months, and 37% thereafter."

19:21 EDT Musk says Twitter may include 'slight cost' for government users - Tesla (TSLA) founder Elon Musk, who recently agreed to acquire Twitter (TWTR), said the platform will always be free for "casual" users, but may include a "slight cost for commercial/government users." Reference Link

18:59 EDT Andersons signs agreement to sell its railcar repair business - The Andersons "announces it has signed an agreement to sell its railcar repair business. The purchase is expected to close this summer."

18:38 EDT Rockwell Automation CEO: It was a tough quarter, below our expectations - In an interview on CNBC's Mad Money, Blake Moret said semiconductor chips needed to build Rockwell's products continue to be "volatile" in supply. He expects improvement in chip supply in Q3 and Q4. Orders continue at historic high levels, he noted. They are broad based across industries the company serves. Moret expects North America to be the fastest growing region in 2022. "We have to raise prices to keep up with costs," he said. He sees very good pricing power in the company's end markets. "We have amazing demand and we're building for the future."

18:05 EDT Caesars says labor still tight, but improving - Says labor costs higher, but "not a considerable drag" on operations. Says customer strength offsetting cost increases. Expects to be "significant free cash flow producer" by year end. Says resilience of gaming customer has been "extraordinary."

17:40 EDT Starbucks says suspending guidance for balance of year 'responsible' - Says inflation increased over the course of Q2. Says a third of stores in China are temporarily closed. Sees China results to continue to be headwind in Q3. Says results for balance of the year will be pressured, particularly in Q3.

17:29 EDT Micross buys discrete diodes and assemblies business of Semtech, no terms - Micross Components announced the acquisition of the High-Reliability Discrete Diodes and Assemblies business of Semtech. Vince Buffa, Chairman and CEO of Micross, said, "We are delighted to partner with this team through the acquisition, to further expands Micross' capabilities. With the addition of significant manufacturing capacity, we will be better positioned to produce an even wider range of high-quality products for our customers. Together, we plan to pursue a number of compelling opportunities to further realize our exciting growth prospects, all while upholding excellent quality and service to our customers."

17:27 EDT Starbucks interim CEO Schultz to remain on board after CEO transition - Sees COVID lockdowns in China for foreseeable future.

17:24 EDT BlueLinx sees efficiently manage volatility in wood-based products to continue - Through the first four weeks of the second quarter 2022, specialty product margins were in the range of 23% to 24% and structural product margins were in the high single digits, reflecting sequential declines in the average price of wood-based commodities. Volumes across both specialty and structural product categories were generally consistent with first quarter levels. The majority of the company's profitability and cash is generated from sales of specialty building products and the company expects demand for specialty building products to remain relatively stable in the coming months. It also expects to continue to efficiently manage volatility in wood-based commodities, a capability the company has demonstrated over the past five quarters," said the company.

17:22 EDT BlueLinx increases share repurchase authorization to $100M - BlueLinx increased share repurchase authorization to $100M, including $60M accelerated share repurchase.

17:18 EDT Starbucks says inflationary pressures have outpaced price increases - Says experienced "negligible" customer attrition in the quarter. Says inflationary pressures have outpaced price increases. Says unable to predict China performance due to COVID. Says situation in Shanghai "unprecedented."

17:12 EDT EnLink Midstream issued its 2021 Sustainability Report - EnLink Midstream issued its 2021 Sustainability Report. The digital report showcases EnLink's sustainability achievements during 2021, including progress on the company's 2024 and 2030 emissions intensity reduction goals. Through the Q1, EnLink accomplished approximately 40% of its goal to reduce methane emissions intensity by 30% by 2024 with a capital investment of less than $800,000 and believes it can achieve the remainder with approximately $2M. EnLink also made progress on its goal to reduce CO2e emissions intensity by 30% by 2030 with projects such as the 15-year agreement with Continental Carbonic Products to purchase carbon dioxide emitted from our Bridgeport plant in North Texas for use in food-grade products, which was announced in November 2021. This project, which requires only a modest investment but carries an attractive return, is expected to be in service in early 2024 and will result in meaningful progress toward our goal of a 30% reduction in total CO2e emissions intensity by 2030. EnLink will continue to focus on cost-effective ways to achieve its environmental goals.

17:10 EDT Connect Biopharma announces top-line results for CBP-307 trial - Connect Biopharma announced top-line results at 12 weeks from its Phase 2 trial for CBP-307, a once-daily, orally administered, selective sphingosine 1-phosphate, or S1, receptor modulator in development for the treatment of ulcerative colitis, or UC. Administration of CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares, or LS, mean change from baseline in adapted Mayo Score at Week 12 that did not meet statistical significance. A significantly higher proportion of patients who received CBP-307 0.2 mg dose achieved Clinical Remission based on both the complete and adapted Mayo Scores, which has been accepted by the FDA as the primary endpoint in clinical trials that have supported prior approvals for treatments of UC. Additionally, reductions in lymphocyte counts amongst individuals receiving CBP-307 0.2 mg confirmed pharmacodynamic activity of CBP-307 in patients with active UC. The primary endpoint of LS mean change from baseline in adapted Mayo Score at Week 12 for CBP-307 0.2 mg and placebo were -2.65 and -2.01, respectively. Secondary endpoints that were met for CBP-307 0.2 mg included a significantly higher proportion of patients reaching Clinical Remission compared to placebo as measured by both adapted and complete Mayo Scores, respectively. For patients receiving CBP-307 0.2 mg, significant improvements were also noted for change in complete Mayo Score from baseline to Week 12 and in Clinical Response as measured by complete Mayo Score. Analysis of exploratory pharmacodynamic endpoints showed that patients receiving CBP-307 0.2 mg demonstrated a mean percent lymphocyte count reduction from baseline of 51.2% with mean absolute lymphocyte counts reduced to approximately 0.8 at week 12. Across the CBP-307 0.2 mg and placebo groups, the occurrence of drug-related treatment emergent adverse events, or TEAEs, was 66% and 38.5%, respectively. In addition, CBP-307 0.2 mg and placebo groups were similar in the occurrence of Grade 3 or higher TEAEs and Serious TEAEs. There were no cases of progressive multifocal leukoencephalopathy and no deaths. The overall safety results in this study showed CBP-307 to be generally well tolerated in patients with moderate-to-severe UC. Given the safety findings along with the efficacy results of this study, the company believes that CBP-307 warrants further clinical development in UC.

16:53 EDT Goldenbridge Acquisition terminates merger agreement with AgiiPlus - Goldenbridge Acquisition announced that it has terminated its previously announced agreement and plan of merger with AgiiPlus, by mutual agreement of all relevant parties. As a result, Goldenbridge will seek an alternative business combination.

16:51 EDT AVCT announces Patel and Koeneman to lead 'cloud' with Kandy - American Virtual Cloud Technologies announced several changes to its management team, including the addition of two new senior executives: Chief Product Officer Jay Patel and Chief Revenue Officer Chris Koeneman who will both report directly to AVCT's Chief Executive Officer Darrell J. Mays. Kevin Keough transitioned from the role of President into the role of Chief Transformation Officer and is also reporting to Mr. Mays. "Jay and Chris bring a wealth of relevant industry experience and expertise to our cloud-based, real-time communications platform Kandy that will be instrumental in helping drive a new strategy going forward," said Mr. Mays. "In recent months, Kandy has developed and aligned around a refined cloud communications strategy; Kevin's role will be to work with the team to drive the comprehensive transformation to this new strategy," said Mays. Patel joins Kandy following his role as Chief Product Officer at Vonage where he led the product management for Unified Communications as a Service (UCaaS), Contact Center as a Service , and Communications platform as a Service product lines. Mr. Patel spent 27 years with Motorola and Motorola Mobility, ultimately serving as the Vice President of Strategy following Motorola Mobility's sale to Google and Vice President of Engineering, following the division's sale to Lenovo. He holds a Bachelor of Science in Electrical Engineering from the University of Illinois at Chicago.

16:48 EDT BuzzFeed names Marcela Martin president - BuzzFeed (BZFD) announced that Marcela Martin will join BuzzFeed, Inc. as President. Martin is currently the CFO of Squarespace (SQSP). Martin will join the company this summer and oversee all of BuzzFeed Inc.'s administrative functions. Martin will be based in New York City and report directly to Founder and CEO Jonah Peretti. "As the first pure play digital media company to go public, we are just beginning to tell BuzzFeed's story to the investment community. I am confident Marcela's extensive background and broad perspective will make her an excellent partner in that pivotal work," said BuzzFeed, Inc. Founder and CEO Jonah Peretti. "Marcela brings a wealth of public company experience in leading cross-functional teams, as well as evaluating and executing transactions, both of which will be invaluable to BuzzFeed's next chapter of growth and profitability."

16:46 EDT U.S. Energy buys $1M oil -gas producing properties in an all-cash transaction - U.S. Energy announced that the Company has acquired operated oil and gas producing properties in an all-cash transaction The Properties are located primarily in Liberty County, TX adjacent to the Company's existing assets in the area.

16:43 EDT Northern Oil and Gas increases quarterly dividend 36% - Northern Oil and Gas announced that its board has declared a cash dividend on the company's common stock in the amount of 19c per share, representing a 36% increase from the prior quarterly dividend. The dividend is payable on July 29 to stockholders of record as of the close of business on June 29.

16:42 EDT Myriad expands partnership with Intermountain Precision Genomics - Myriad Genetics announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to its growing oncology portfolio. Compared to standard tissue biopsies, many oncologists prefer liquid biopsy testing to analyze traces of tumor DNA in the blood, providing an often quicker, less invasive alternative for cancer treatment selection. For many patients, liquid biopsy is necessary when tissue sampling is not feasible. Liquid biopsy therapy selection testing can be used to support the care of all patients with advanced cancer.

16:42 EDT BWX Technologies names Jan Bertsch chair of the board - BWX Technologies announced that Jan A. Bertsch has been elected as its new chair of the board of directors, effective May 3, 2022, succeeding retiring board chairman John A. Fees. Bertsch has served as an independent director of BWXT since 2013, and she was most recently the chair of its audit and finance committee and a member of the compensation committee. She also serves on the board of directors of Meritor and its audit and governance committees, as well as the board of directors of Regal Rexnord and its audit and compensation committees. "We are extremely fortunate to have someone of Jan's caliber assume this important leadership position for our company," said Rex Geveden, BWXT's president and chief executive officer. "Jan's tenure on our board goes back to before the spinoff of our power generation business in 2015, and her deep engagement on our board makes her an ideal fit for this new role."

16:40 EDT Masonite expects to meet or exceed FY22 outlook - "We are very encouraged by our strong financial performance in the first quarter but recognize that the macro environment in both North America and Europe is rapidly evolving," said Russ Tiejema, Executive Vice President and CFO. "The entire Masonite team is focused on optimizing our operations while driving forward our Doors That Do More Strategy. At this time, we are optimistic that we can meet or exceed the 2022 full year outlook we provided in February."

16:38 EDT Mission Produce appoints Timothy Bulow as President and COO - Mission Produce announced it has named Timothy Bulow as President and Chief Operating Officer, effective no later than August 1 . Mission's Founder Steve Barnard will continue to serve in his role as Chief Executive Officer and a member of the Board of Directors. Bulow joins Mission with more than 30 years of experience leading global operations, business development and marketing for consumer-facing businesses across diverse geographies and industries. He has deep experience with multi-national consumer goods corporations, including General Mills, Inc., where he served in multiple general management and marketing leadership positions, introducing multiple branded products and streamlining operations in international markets across Latin America, Europe, and Asia. Most recently, Bulow served as Chief Operating Officer at Minor Education, part of Minor International, one of the largest hospitality, restaurant and lifestyle companies in the Asia Pacific Region. In this role, Bulow was responsible for the development, strategic market expansion, and launch of new education platforms. Bulow began his career at KPMG before joining PepsiCo, Inc., where he held various roles in accounting, finance and strategy. Bulow earned a B.S. in business from Tennessee Tech University and an MBA from Harvard Business School.

16:36 EDT Bell Industries to sell Sofpironium Bromide to Botanix Pharmaceuticals - Brickell Biotech announced that it has signed and closed a definitive asset purchase agreement with Botanix SB a subsidiary of Botanix Pharmaceuticals whereby Botanix has acquired the Company's rights to sofpironium bromide, a retrometabolically-designed new chemical entity that belongs to a class of medications called anticholinergics. Sofpironium bromide gel, 15% is a potential best-in-class topical therapy that recently completed a U.S. Phase 3 pivotal clinical program for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. Brickell was on track to submit a New Drug Application to the U.S. FDA for sofpironium bromide gel, 15% in mid-2022. Under the terms of the agreement, Botanix has acquired from Brickell all assets primarily related to sofpironium bromide. In exchange, Brickell will receive upfront and potential near-term regulatory milestone payments over the next 18 months of up to $9 million from Botanix. Brickell also is eligible to receive additional success-based regulatory and sales milestone payments of up to $168 million and tiered earn out payments ranging from high-single digits to mid-teen digits on net sales of sofpironium bromide gel. Certain of these amounts are subject to payments by Brickell to its former licensor. Botanix will be responsible for all further research, development, and commercialization of sofpironium bromide globally. In connection with the sale of sofpironium bromide, Brickell and Botanix entered into a transition services agreement whereby Brickell will provide consulting services to Botanix through submission and potential approval of the U.S. NDA for sofpironium bromide gel, 15%.

16:35 EDT Yum China says 'Omicron variant caused significant volatility in our business' - The company said, "The highly transmissible Omicron variant caused significant volatility in our business operations in the first quarter, and continues to have a severe impact in the second quarter. The COVID-19 situation was relatively stable in January and February. However, the situation rapidly deteriorated in March, resulting in the largest outbreak since COVID-19 first emerged in early 2020. This latest outbreak and the challenges we face are unprecedented. Compared to first quarter 2020, the case counts, duration, geographical coverage and restrictive measures experienced in the first quarter 2022 are much more severe."

16:34 EDT Yum China sees FY22 CapEx $800M-$1B - Expects to open approximately 1,000-1,200 net new stores in 2022.

16:26 EDT Blackbaud sees FY22 CapEx $60M-$70M - Including approximately $45M-$55M of capitalized software development costs

16:25 EDT Bright Horizons to acquire Only About Children for about $320M - Bright Horizons announced that it has signed a definitive agreement to acquire all of the outstanding shares of Only About Children, an operator of child care and early education centers in Australia, for A$450, or approximately $320M. "We are excited to welcome Only About Children to the Bright Horizons family," said Bright Horizons CEO Stephen Kramer. "We have long been interested in Australia as an attractive market for high-quality child care, with strong demand from working parents, an established funding support system, and a long runway for growth and expansion." The transaction is expected to be approximately neutral to Bright Horizons' adjusted earnings per share in the first year as the integration of this full service child care business is completed, and to be accretive thereafter. The transaction is expected to close in the third quarter of calendar 2022, subject to certain customary closing conditions, including Australian foreign investment regulatory approval, customary purchase price adjustments, and will be financed with cash on hand and amounts borrowed under Bright Horizons' existing revolving credit facility. Under the terms of the transaction, Bright Horizons will pay A$300M upon closing and an additional A$150M will be paid eighteen months after closing as deferred purchase price. Bright Horizons has entered into a foreign exchange forward contract arrangement to mitigate the impact of foreign currency fluctuations between signing and closing.

16:21 EDT Gulfport Energy reports Q1 net production 1,008 MMcfe per day - Reported $492.0 million of net loss and $235.3 million of adjusted EBITDA. "Gulfport reported strong first quarter 2022 results, driven by the continued outperformance of our 2021 development program, excellent uptime during the winter months and the addition of five new SCOOP wells performing above expectations. As a result, we generated significant free cash flow, which allowed us to begin executing on our common stock repurchase program while maintaining a strong financial position and leverage below 1.0x," commented Tim Cutt, CEO of Gulfport. "Our outlook for free cash flow continues to improve, despite the growing inflationary effects that has led us to increase our capital outlook for the year. Our development program builds during the second quarter, before peaking in the third, which results in executing a high percentage of our program at higher service rates."

16:17 EDT KAR Auction raises share repurchase authorization by $200M - The board of directors authorized an increase in the size of the company's $300M share repurchase program by an additional $200M and an extension of the share repurchase program through December 31, 2023. With the increase, and giving effect to the company's previous repurchases, approximately $309M remains available for repurchases under the share repurchase program.

16:13 EDT Airbnb reports Q1 Gross Booking Value up 67% to $17.2B - Airbnb said: "In Q1 2022, we exceeded 100 million Nights and Experiences Booked, our largest quarterly number ever. GBV of $17.2 billion and revenue of $1.5 billion in Q1 2022 were both more than 70% higher than pre-pandemic Q1 2019 levels. And through our focus and discipline, we delivered $229 million of Adjusted EBITDA, $1.2 billion of net cash provided by operating activities and $1.2 billion of free cash flow in the quarter."

16:12 EDT Western Midstream names Kristen Shults as new CFO - Western Midstream Partners announced the appointment of Kristen Shults to Senior Vice President and Chief Financial Officer, effective on May 2, 2022. In this role, Shults will continue to lead the organization's Finance, Investor Relations, Communications, and Sustainability teams, with additional oversight of the Accounting organization. Shults joined Western Midstream in 2019 as Vice President, Investor Relations and Communications, and most recently served as Senior Vice President, Finance and Sustainability.

16:11 EDT Starbucks reports Q2 global comparable sales up 7% - Global comparable store sales increased 7%, driven by a 4% increase in average ticket and a 3% increase in comparable transactions. North America and U.S. comparable store sales increased 12%, driven by a 7% increase in average ticket and a 5% increase in comparable transactions. International comparable store sales decreased 8%, driven by a 5% decline in average ticket and a 3% decline in comparable transactions; China comparable store sales decreased 23%, driven by a 20% decline in comparable transactions and a 4% decline in average ticket. International and China comparable store sales include the unfavorable impact of approximately 3% and 4%, respectively, from lapping prior-year value-added tax exemptions in China, the company said. The company opened 313 net new stores in Q2, ending the period with 34,630 stores globally: 51% company-operated and 49% licensed. At the end of Q2, stores in the U.S. and China comprised 61% of the company's global portfolio, with 15,544 stores in the U.S and 5,654 stores in China.

16:09 EDT A10 Networks backs FY22 EBITDA growth view 26%-28% - "We believe we are now well-positioned to achieve the high end of our full year targets around top line growth of 10 - 12% and expanding EBITDA in the range of 26 - 28%," continued Trivedi.

16:05 EDT Kezar Life Sciences says most patients saw improvements in TIS in Presidio trial - Kezar Life Sciences announced topline results from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis. In PRESIDIO, 25 patients enrolled with either DM (n=13) or PM (n=12) with active disease despite best available treatments, and 20 patients completed through end-of-treatment. During the 32-week study period, all patients received 16 weeks of zetomipzomib treatment: patients received either 45 mg of zetomipzomib or placebo subcutaneously (SC) once weekly for 16 weeks on top of standard of care, followed by a crossover to the other arm of placebo or zetomipzomib, respectively, for an additional 16 weeks. Patients continued their background therapy but could taper medications as clinically indicated. The primary endpoint of PRESIDIO was the mean change in the Total Improvement Score (TIS). Topline results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in TIS, but zetomipzomib demonstrated no significant differentiation from placebo. At Week 16, the zetomipzomib 45 mg SC weekly group achieved a mean TIS of 25.5 versus the control group mean TIS of 25. Following cross-over, at Week 32, the arm receiving zetomipzomib beginning at Week 16 achieved a mean TIS of 32.5 versus the control group mean TIS of 31.3.

15:59 EDT Intel acquires Finnish technology company Siru Innovations - Balaji Kanigicherla, Vice President at Intel, announced in a LinkedIn post that the company has acquired Siru Innovations, a Finnish technology company specializing in the development of graphics IP and software services. "We are thrilled to welcome CEO Mikko Alho and the entre Siru Innovations team to Intel and the Accelerated Computing Systems and Graphics Group. Siru adds critical GPU talent that will support Intel's pursuit of leadership graphics IP. Their expertise spans architecture, software, modeling and hardware implementation. Together, we will propel AXG and the Custom Compute Group's focus on driving custom silicon/platform solutions and emerging accelerated compute solutions, in the areas of blockchain, Metaverse, high performance edge compute and hyperscale - representing a significant opportunity over the coming years." Reference Link

14:52 EDT DXP Enterprises announces acquisition of Cisco Air Systems - DXP Enterprises announced that it has completed the acquisition of Cisco Air Systems, a distributor of air compressors and related products and services focused on serving the food & beverage, transportation and general industrial markets in the Northern California and Nevada territories. Signing of the definitive agreements occurred on May 2. Sales and adjusted EBITDA for Cisco for the last twelve months ending March 31, 2022 were approximately $43.2M and $7.0M, respectively. Financial terms of the transactions were not disclosed. DXP funded the acquisition with cash from the balance sheet and DXP Enterprises common stock as consideration, the company noted. "We are pleased to announce the acquisition of Cisco and the first-tier capabilities, strong leadership and complete business model as a part of our air compressor growth efforts. We are excited to have Cisco join the DXP family. Cisco provides DXP with exceptional sales expertise that will enhance our efforts and our ability to collaborate and serve our customers. This acquisition is consistent with our growth strategy and demonstrates our commitment to expanding DXP into other products, markets and capabilities as well as maintaining our leading position as the largest distributor of rotating equipment in North America," commented David Little, CEO of DXP.

14:10 EDT Google expands Google Career Certificates program - Alphabet's Google said yesterday it is expanding its Google Career Certificates program to further meet the needs of businesses and job seekers. To make it easier for businesses to help their employees get the skills they need, beginning today, U.S. businesses can get up to 500 scholarships each to Google Career Certificates to train their employees. These scholarships are worth up to $100,000 in workforce training per American company. It's no secret that businesses of all sizes are struggling to acquire and retain talent. Those who create growth opportunities for their employees have a much better shot at retaining them. Businesses can use Google Career Certificates to train their employees for jobs in data analytics, digital marketing & e-commerce, IT support, project management or user experience design. No experience is required, and employees can earn an industry recognized credential in three to six months of part-time study. In addition, to ensure businesses of all sizes can use digital marketing and e-commerce to unlock growth opportunities - and that they have access to talent with the know-how - Google is launching a new Digital Marketing & E-commerce Certificate. This certificate teaches digital marketing and e-commerce skills, including how to find customers, building an online store, measurement and analytics and increasing customer loyalty.

13:26 EDT Subaru reports April U.S. sales down 25.5% to 45,748 vehicles - Subaru of America reported 45,748 vehicle sales for April, a 25.5% decrease compared with April 2021. The automaker also reported year-to-date sales of 178,094, a 19.7% decrease compared with the same period in 2021. "Subaru continues to face inventory challenges as the result of microchip and supply chain issues affecting automakers across the globe," the company stated.

13:26 EDT Blizzrad unveils new mobile game 'Warcraft Arclight Rumble' - Activision Blizzard's (ATVI) Blizzard Entertainment unveiled "Warcraft Arclight Rumble," an action-packed mobile strategy game coming later this year to Android and iOS devices in select regions. Designed from the ground up for mobile and set in the "Warcraft" universe, "Warcraft Arclight Rumble" invites players to build armies with their favorite heroes and villains from "Warcraft" and battle it out in unique missions designed to test their tactical wits. "Warcraft Arclight Rumble provides the sort of experience that we always strive to create at Blizzard," said Mike Ybarra, President of Blizzard Entertainment. "It's instantly fun, yet deep and rewarding over the long term, and we're immensely proud to bring a new and authentic representation of Warcraft to mobile. We can't wait for players to experience the joyful chaos of this game for themselves." Players will continually earn in-game currency to add to and level-up their collections by simply playing the game or through purchases from the in-game shop. Starting soon, select players in certain regions will be able to join the beta test for "Warcraft Arclight Rumble." The Fly notes that Activision Blizzard shareholders recently approved the company's takeover by Microsoft (MSFT).

13:14 EDT Ubisoft moves 'Prince of Persia' remake development to new studio - Ubisoft said that development of the upcoming remake of "Prince of Persia: The Sands of Time" will now be lead by Ubisoft Montreal. "This decision is an important step and the team, building upon the work achieved by Ubisoft Pune and Ubisoft Mumbai, will now take the time they need to regroup on the scope of the game to deliver you the best experience for this remake of an all-time classic, when it's ready," the company said. The Fly notes that Ubisoft has delayed this title multiple times since it's announcement in 2020. Reference Link

13:07 EDT Sanofi announces distribution of cash dividend, ratio for EUROAPI distribution - Sanofi announced its combined general shareholders' meeting was held on May 3, at which all resolutions submitted to the vote were adopted by the shareholders. The general meeting approved the individual company and consolidated financial statements for the fiscal year 2021. The general meeting decided on the distribution of an ordinary annual dividend of EUR 3.33 per share and an additional dividend in kind in the form of an allocation of EUROAPI shares, at a ratio of one EUROAPI share per twenty-three Sanofi shares held. The payment of the dividend, including both the cash dividend and the dividend in kind, will be made on May 10. The general meeting also renewed Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp as directors, and approved the appointment of Carole Ferrand, Emile Voest and Antoine Yver.

12:41 EDT Energy Transfer LP signs LNG sale and purchase agreement with SK Gas Trading - Energy Transfer LP announced the execution of a long-term Sale and Purchase Agreement with SK Gas Trading LLC (SK Gas) for the supply of 0.4 million tonnes per annum of LNG from Energy Transfer's Lake Charles LNG export facility. Under the SPA, Energy Transfer LNG Export, LLC will supply LNG to SK Gas on a free-on-board basis. The purchase price is indexed to the Henry Hub benchmark plus a fixed liquefaction charge. The SPA is for a term of 18 years, and first deliveries are expected to commence as early as 2026. The SPA will become fully effective upon the satisfaction of the conditions precedent, including Energy Transfer LNG taking final investment decision. This is Energy Transfer's fourth SPA announced in the last four weeks, bringing the total amount of LNG contracted from its Lake Charles LNG export facility to 5.1 mtpa, the company said in a statement.

12:23 EDT Newmark acquires Open Realty, terms not disclosed - Newmark Group announces the acquisition of North American retail real estate advisory firms Open Realty Advisors and Open Realty Properties. Open Realty will join Newmark's Retail Services business line with an extensive national and global client roster, and its founders will assume significant leadership roles to expand Newmark's global retail footprint. Open Realty is led by Mark Masinter, who heads the firm's macro strategy and business development, Johnny Siegel, who spearheads tenant advisory services and asset management strategies for clients, and Steve Merkle, who co-leads tenant advisory business endeavors. Masinter and Siegel join Newmark as Chairman of Global Retail and President of Global Retail, respectively; Merkle joins as Vice Chairman. Open Realty specializes in tenant strategic planning, site identification, lease negotiation, project administration, construction and design facilitation, portfolio maintenance and site disposition, as well as project-specific expertise in acquisition consultation, project design and site development, merchandising, project leasing and asset management, and overall market and financial analysis.

12:02 EDT Harsco falls -19.4% - Harsco is down -19.4%, or -$1.99 to $8.29.

12:01 EDT eXp Realty to expand operations into Chile, Dubai - eXp Realty announced plans to expand its real estate operations into Chile and Dubai, United Arab Emirates. This announcement follows successful launches of nine new markets in 2021, and two year-to-date including Dominican Republic and Greece, with New Zealand expected to open this month. Upon launch of these new markets, eXp Realty expects to have a presence in 23 territories, including its headquarters in the United States

12:00 EDT Blue Apron rises 15.0% - Blue Apron is up 15.0%, or 60c to $4.64.

11:37 EDT DuPont, Markforged to print live parts with Kevlar at JECWorld - Markforged (MKFG) and Dupont (DD) will be printing live parts with Kevlar at JECWorld, Markforged said via Twitter. "Stop by Dupont's booth to learn more about what this tough, highly durable Continuous Fiber can do for your manufacturing process, and feel the Markforged difference for yourself." Reference Link

11:31 EDT Western Digital says will 'carefully consider' Elliott's ideas - Western Digital issued a statement regarding a letter sent by Elliott Management to its board which reads in part: "Western Digital maintains an ongoing dialogue with our shareholders and values constructive input on our business. We agree that Western Digital is an excellent, yet undervalued, company with strong positions in our flash and HDD businesses and look forward to engaging with Elliott to discuss their views. Our Board of Directors is committed to acting in the best interests of all our shareholders and will carefully consider Elliott's ideas. Western Digital is a leading data infrastructure company focused on executing its strategy to capitalize on the huge market opportunity stemming from the rapid global adoption of the cloud and the expansive and growing ecosystem it supports. Our end market diversity and breadth, restructured organization, broad customer base, channel reach and innovative product leadership all position the company to benefit from the multi-year growth in data creation and storage. We will continue our commitment to innovation and our focus on delivering the quality, performance and cost-effectiveness our customers rely on. Our CEO, David Goeckeler and the Board of Directors have explored a range of options to unlock and deliver long-term value and we will continue our ongoing dialogue with our shareholders."

10:55 EDT Puxin Limited trading halted, news pending

10:23 EDT Hilton seeing 'nice uptick' in return to business transient

10:10 EDT Citius Pharmaceuticals provides business updates, upcoming milestones - Citius Pharmaceuticals provided a business update for the first quarter ended March 31, 2022 and reported on recent corporate developments and upcoming milestones. Recent Highlights and Upcoming Milestones: Citius anticipates filing a biologics license application for I/ONTAK with the U.S. Food and Drug Administration in the second half of 2022; Topline data from the Phase 3 study of cancer immunotherapy I/ONTAK are consistent with the previously-approved formulation of denileukin diftitox, and there are no new safety signals; Halo-Lido Phase 2b trial initiated in April 2022 with last patient enrollment anticipated by the end of 2022; Phase 3 Mino-Lok trial proceeding without modification as recommended by the independent data monitoring committee following all three DMC reviews; Mino-Lok Phase 3 trial completion anticipated by end of 2022; and, Pre-clinical development ongoing for Citius' Mino-Wrap and induced mesenchymal stem cell programs. "2022 is a year of important catalysts for Citius as we continue to make progress on multiple fronts. We recently released topline results for I/ONTAK which were consistent with the prior FDA-approved and marketed formulation of denileukin diftitox. In preparation for a planned BLA submission in the second half of 2022, we are marshalling the necessary manufacturing and commercial resources to support the application, and ultimately a successful launch," stated Leonard Mazur, Chairman and CEO of Citius. "Our Mino-Lok program continues to advance in accordance with the recommendations of the independent data monitoring committee, which advised us to continue with the trial as planned, following each of its three data reviews. We remain encouraged by the positive signal conveyed by the DMC guidance to proceed. Coupled with the recent ramp up in patient recruitment following an easing of COVID-related hospital restrictions, we believe our efforts to increase engagement with existing trial sites and to onboard additional sites will continue to drive trial enrollment and enable us to achieve the necessary trial events to support statistically significant results. In April, we initiated our Phase 2b Halo-Lido trial for the treatment of hemorrhoids. By the end of 2022, we expect to complete trial enrollment. A data readout will follow upon validation and analysis of the information provided in the electronic patient reported outcome tool designed with guidance from the FDA. The results will be used to design the Phase 3 trial. As this product would ultimately be marketed directly to consumers, rather than to targeted physician and hospital groups like our other pipeline candidates, we will evaluate alternatives to optimize the value of this asset as we advance the program. Citius considers all strategic alternatives to maximize the value of our portfolio, individually and collectively, on an ongoing basis. We believe we remain well capitalized to advance our programs through multiple catalysts this year, and we plan to continue building long-term value in the business by focusing on execution," concluded Mr. Mazur.

10:09 EDT RenovaCare terminates StemCell Systems agreement, closes Berlin center - RenovaCare announced the termination of its July 1, 2020 Strategic Research and Development Agreement with StemCell Systems and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany. This decision ceases on-going development of the prototype for the closed, automated Cell Isolation Device and the portable, disposable SkinGun spray device. Development may resume at SCS or other Contract Manufacturing Organizations, upon the availability of adequate funds. As previously announced, the Company has suspended patient enrollment in its clinical study for the evaluation of the safety and feasibility of the manual CellMist System and its electronic SkinGun spray device as an autologous stem cell treatment of adult burn patients. Patients previously enrolled and treated with RenovaCare therapies and technologies will continue to receive ongoing care as per the FDA protocol. The clinical study and IDE remain open for possible resumption, and enrollment in the study may continue if capital funding becomes available in the future, for which there can be no assurances.

10:06 EDT Hilton to return $1.4B-$1.8B to shareholders via buybacks, dividends this year - Hilton has completed 265M of buybacks through April, the company said on its Q1 earnings conference call.

10:05 EDT FanDuel names David Jennings CFO - FanDuel Group announced that it has appointed David Jennings as the company's CFO. Jennings will be responsible for oversight of all FanDuel's finance functions including FP&A, strategy, accounting, procurement, tax and treasury in support of the company's Sportsbook, Casino, Racing, Daily Fantasy, Retail and corporate functions. FanDuel Group is a subsidiary of Flutter Entertainment. Jennings joins FanDuel from parent company Flutter where he served as Group Director of Investor Relations and FP&A.

10:00 EDT Harsco falls -23.1% - Harsco is down -23.1%, or -$2.38 to $7.90.

10:00 EDT Catalent rises 11.9% - Catalent is up 11.9%, or $10.71 to $100.83.

10:00 EDT Atkore rises 18.2% - Atkore is up 18.2%, or $17.54 to $113.87.

09:50 EDT Alpine 4 Holdings' Quality Circuit Assembly receives $2.2M in orders - Alpine 4 Holdings' Quality Circuit Assembly has received $2.2M in new orders from its EV customers. The company expects demand for its US assembled circuit boards and wire harnesses to continue well into 2023, as OEMs continue their push for domestic based components.

09:47 EDT Hayward falls -11.3% - Hayward is down -11.3%, or -$1.90 to $14.98.

09:47 EDT Chegg falls -32.1% - Chegg is down -32.1%, or -$8.01 to $16.97.

09:47 EDT Chemours rises 9.7% - Chemours is up 9.7%, or $3.21 to $36.31.

09:46 EDT Exxon Mobil to sell Romanian affiliate to Romgaz for more than $1B - ExxonMobil announced an agreement to sell its Romanian upstream affiliate, ExxonMobil Exploration and Production Romania, to Romgaz for more than $1B, subject to Romanian government approvals. The agreement includes all shares in ExxonMobil Exploration and Production Romania along with interest in the XIX Neptun Block offshore Romania. Operatorship on the block will transfer to its other titleholder, OMV Petrom. Employees of the Romanian affiliate will transfer as part of the sale. ExxonMobil has been present in Romania's upstream sector since November 2008, when it acquired an interest in the deepwater Neptun Deep block in the Black Sea. The transaction is expected to close in the second quarter of 2022. "ExxonMobil continues to evaluate our portfolio of opportunities, focusing our investments in advantaged assets with a low cost of supply. Our investments to date have positioned the Neptun Deep project for future success with potential to help increase resource production within Romania and the European Union," said Liam Mallon, president of ExxonMobil Upstream Company.

09:42 EDT SoundHound AI Inc trading resumes

09:37 EDT Lithium Corp. says Fish Lake Valley claim block has been expanded - Lithium Corporation is pleased to inform shareholders the Fish Lake Valley claim block has been expanded yet again, and the partially completed magnetotelluric survey identified three stand-alone drill targets in the more southerly areas of the claim block. Recently, the Fish Lake Valley claim block increased to approximately 11,020 acres in order to cover basinal lows identified by the earlier passive seismic survey, which possibly could be traps for Li-in-brine mineralization. Additionally, the recent MT survey, conducted on the southern portions of the claim block, identified 3 conductivity targets suggestive of brine mineralization at depth. Two of these targets are adjacent to previously identified structure that coincides with proximal Li-in-clay at surface. The third target is further east and has not been previously identified as an area of interest. The Fish Lake Valley project optionee Morella Corporation indicated they are planning to commence an initial drill program here sometime in the second half of 2022.

09:37 EDT EverQuote trading resumes

09:33 EDT GlobalFoundries awarded $117M DoD chip supply deal - As part of the nation's effort to sustain the microelectronics manufacturing capability necessary for national and economic security, and in support of Executive Order 14017, America's Supply Chains, the Department of Defense said Monday that it has awarded a $117M agreement to GlobalFoundries. GF will transfer its 45 nanometer silicon-on-insulator semiconductor manufacturing process from its Fab 10 facility in East Fishkill, New York, to its Fab 8 facility in Malta, New York. The effort is a follow-on from an $8M award issued last year through which GF conducted initial engineering baseline activities for the transfer. This agreement will ensure access to 45nm SOI semiconductors critical to DoD strategic systems.

09:25 EDT Terreno sells Bound Brook, New Jersey property for $110.4M - Terreno Realty sold an industrial property located in Bound Brook, New Jersey on May 2, for a sale price of approximately $110.4M. The property consists of 18 industrial distribution buildings containing approximately 581,000 square feet on 38 acres which are 100% leased to 29 tenants. The property was purchased by Terreno Realty Corporation on September 24, 2010 for approximately $27.0 million and was 76% leased to 20 tenants at acquisition. The unleveraged internal rate of return generated by the investment was 15.2%.

09:23 EDT Airspan , Guident test AV smart city use at scale using CBRS - Airspan Networks a subsidiary of Airspan Networks Holdings which provides ground-breaking, disruptive software and hardware for 5G network solutions, and Guident are working together to provide customers with connectivity and software solutions for autonomous vehicle and smart city use cases, using CBRS spectrum. Airspan and Guident, developer of software solutions for autonomous vehicles , ground-based delivery drones, and electric vehicles utilizing artificial intelligence algorithms, have successfully deployed a 5G Private Networks testbed based on CBRS at Guident's facility in Boca Raton, Florida. The testbed covers three square miles for developing, testing and validating different use cases that require a fast, reliable network with low latency. One key use case is the driving of autonomous vehicles, which requires rapid decision making to provide enhanced safe driving operation at scale by preventing potential autonomous vehicle accidents before they happen. The testbed features an Airspan AirSpeed system, along with Guident's software platform connected to a Remote Monitoring and Control Center . The combination has proven to have one of the lowest glass-to-glass latency measurements in the market of approximately 30 milliseconds. The innovation developed for this project has resulted in Guident filing for its eighth patent. Airspan will focus on providing and enhancing connectivity with its innovative 5G software, hardware and air interface mobility solutions. Guident is providing it's patented, advanced teleoperation for autonomous and human-driven vehicles, to enhance customer safety and security in addition to providing a reliable, low latency connection to any advanced mobile network.

09:19 EDT Levena Biopharma announces clinical data for A166 in breast cancer - Sorrento Therapeutics announced that its license and development partner, Sichuan Kelun-Biotech Biopharmaceutical, presented at this year's Chinese Society of Clinical Oncology Guideline Conference Phase 1 data for its anti-HER2-ADC, A166. To generate this site-specific third generation ADC, Kelun partnered with Levena Biopharma, a Sorrento company, which provided the proprietary ADC technologies for the generation and production of A166, including a proprietary small molecule toxin, Duostatin-5, a tubulin inhibitor, K-Lock, a site-specific conjugation chemistry and an enzymatically cleavable linker. Compared to Kadcyla, the first Antibody-Drug Conjugate approved for the treatment of HER2-positive metastatic breast cancer, A166 demonstrated potentially better efficacy, as shown in the overall response rate of 73.9% with A166 at 4.8mg/kg versus Kadcyla, which had an ORR of 31.3%, as well as the progression-free survival of 12.3 months with A166 versus 6 months with Kadcyla.

09:15 EDT Future FinTech subsidiary signs power agreement with Champion Energy Services - Future FinTech Group announced that on April 22 its wholly-owned subsidiary, FTFT SuperComputing signed an Electricity Sales and Purchase Agreement with Champion Energy Services. The Agreement stipulates that Champion Energy is obligated to provide 15.58 MW of electricity for the development of the Company's planned cryptocurrency farm in Northwest Ohio. The Agreement has a provision for a hybrid pricing plan that includes a fixed and index combination and is customer-specific to changes in FTFT SuperComputing's energy needs. The start date for the sale and delivery of electricity is anticipated to be July 1, 2022, and the Agreement has a term of six years. Champion Energy is an electricity provider that services residential, governmental, commercial and industrial customers in eight states. They are a subsidiary of Calpine, one of the largest generators of electricity in the US.

09:11 EDT Rite Aid and Block unit Afterpay partner to offer BNPL on everyday items - Block (SQ) unit Afterpay "the leader in "Buy Now, Pay Later BNPL payments, and trusted care retailer Rite Aid (RAD)," said the statement" announced their partnership offering Rite Aid's online shoppers a new way to pay for everyday items in four installments at no additional cost when you pay on time.

09:09 EDT EnWave signs Technology Evaluation, License Option Agreement with Goldencrops - EnWave Corporation announced that it has signed a Technology Evaluation and License Option Agreement with Goldencrops Corporation, a Southeast Asian ingredient manufacturer, to evaluate the commercial use of the Company's Radiant Energy Vacuum dehydration technology for the production of a variety of fruit, dairy and grain products. Goldencrops will rent a 10kW REV machine for intensive product development at its manufacturing facility in Douliu City - an industrial hub for food production in the region. If commercially viable ingredients are developed under the Agreement, Goldencrops will then purchase REV machinery to commence commercial production at its Yunlin Science and Technology Plant. Goldencrops is looking to leverage EnWave's proprietary REV dehydration technology to expand its dehydrated ingredient product offerings for domestic and international markets.

09:07 EDT DraftKings announces Metabilia to become latest NFT supplier on its marketplace - DraftKings has teamed up with Metabilia, a memorabilia and NFT company operating at the forefront of physical and digital collectibles, which will become the latest NFT supplier on DraftKings Marketplace. The collaboration introduces "Membership NFTs" for fans to chronicle the careers of young players and will feature star major leaguers beginning with Vladimir Guerrero Jr., Ronald Acuna Jr., Shane Bieber, Wander Franco, Joe Musgrove, and Fernando Tatis Jr. Metabilia has relationships with elite athletes and teams to help engage their fanbases through NFT projects and drops. This collaboration with Metabilia is consistent with DraftKings' long term goal to bring top sports NFT creators to DraftKings Marketplac. DraftKings Marketplace has incorporated many iconic sports stars to date.

09:06 EDT Uber, Albertsons expand partnership - Uber Technologies (UBER) and Albertsons (ACI) announced the expansion of their partnership to include more than 2,000 of the grocer's banner stores nationwide, including Albertsons, Safeway, Jewel-Osco, ACME, Tom Thumb, Randalls and more through Uber Eats. This expansion brings nearly 800 new locations to Uber Eats including to consumers in Connecticut, Indiana, New Hampshire, Utah, Vermont, and Rhode Island for the very first time. To enable this growth, Albertsons Cos. stores are more accessible within the Uber Eats app than ever before. Now, in addition to stores being found within Uber Eats' grocery category, consumers can order their favorite items for delivery through 'express' lanes within the convenience section of the app. Uber One members benefit from $0 Delivery Fee on all convenience orders from Albertsons Cos 'express' stores with $15 minimum purchase.

09:05 EDT Progenity to report Q1 results as Biora Therapeutics - Progenity announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics will coincide with the earnings call on May 10. The company's NASDAQ ticker symbol will also change from "PROG" to "BIOR" on that day. No action is needed from current stockholders. The company's common stock will continue to be listed on NASDAQ and the CUSIP will not change.

09:04 EDT Riot Blockchain produced 508 BTC in April, up 150% year-over-year - Riot Blockchain announces production and operations update for April 2022.Bitcoin Production and Operations Updates: In April 2022, Riot produced 508 BTC, an increase of approximately 150%, as compared to April 2021 production of 203 BTC. As of April 30, 2022, Riot held approximately 6,320 BTC, all produced by the Company's self-mining operations. In April 2022, Riot sold 250 Bitcoin generating net proceeds of approximately $10M. Riot currently has a deployed fleet of approximately 46,375 miners, with a hash rate capacity of 4.7 exahash per second. "April marks yet another incredible milestone for Riot, with the announcement of the Company's 1 gigawatt Expansion in Navarro County, Texas," said Jason Les, CEO of Riot. "Our ability to source and manage this second significant expansion opportunity in Texas exemplifies the Company's partnership-driven approach with all stakeholders, including the Company's business partners, ERCOT, and all levels of government, to commit to sustainable economic development. We are excited to build upon our demonstrated ability to develop high-quality, large-scale digital infrastructure, leveraging our experienced employee base and opening the doors to new jobs and economic opportunities in Navarro County."

09:04 EDT Iteris awarded $2M contract from City of Concord for sustainability program - Iteris announced that it has been awarded a $2M contract by the City of Concord for a smart mobility, safety and sustainability program representing continued demand for Iteris' advanced detection systems in northern California, a key geographic market. Under the terms of the five-year contract, which is extendable for two additional one-year periods, Iteris will upgrade key intersections and arterials in Concord, California with hybrid video and radar detection systems to support the city's goals of improving traffic flow and safety, and reducing carbon emissions.

09:03 EDT Hyundai Motor America reports April retail sales of 61,668 units, down 20% y/y - Hyundai Motor America reported April retail sales of 61,668 units, its second-best April retail sales month in its history. Electrified vehicle year-over-year retail sales increased 68% in April. Hyundai had no fleet sales in April 2022. Elantra Hybrid, Santa Fe Hybrid, Palisade and Nexo set new April records, while it was the best month ever for Santa Cruz.

09:01 EDT Torrid names Liz Munoz chief creative officer, Tanner MacDiarmid interim CFO - Torrid announced changes to the senior leadership team and board of directors, including the appointment of Liz Munoz to a new role as chief creative officer, the appointment of retail industry veteran Lisa Harper as Munoz's successor as CEO, and the appointment of Tanner MacDiarmid as interim CFO, all effective immediately. In conjunction with these organizational changes, Torrid announced that Michael Shaffer, former CFO of PVH Corp., has joined the board of directors as an independent member and chair of the Audit Committee.

08:54 EDT Teva says no major M&A planned for 'next several years' - Says current balance sheet not conducive to M&A.

08:53 EDT Expion360 secures $300,000 line of credit from GM Financial - Expion360 has secured a $300,000 credit line from GM Financial to expand its fleet of mobile product demonstration vehicles and sales force. Expion360 will initially use a portion of the credit line to purchase several new GM trucks, which will be used for the expansion of its regional sales territories across Utah, Arizona, Texas, Indiana and the Southeast. The new Expion360-branded trucks will be specially outfitted to demonstrate and provide samples of the company's advanced lithium iron phosphate batteries and accessories designed for mobile and stationary power applications.

08:51 EDT Jaguar Health files for conditional new animal drug approval of Canalevia - Jaguar Health announced that it has completed filing of the final regulatory section with the U.S. Food and Drug Administration's Center for Veterinary Medicine to support conditional new animal drug approval of the company's oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea in dogs. In December of 2021, Jaguar Animal Health received conditional approval from the FDA for Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. Conditional approval is an FDA drug approval pathway for animal products under The Minor Use and Minor Species Animal Health Act of 2004. As previously announced, the CVM has already confirmed the completeness of three of the four major required technical sections of Jaguar Animal Health's application for conditional approval of Canalevia for EID.

08:46 EDT Envela's DSGE plans to accelerate expansion plans - DGSE announced that after a record first quarter it plans to accelerate expansion plans. With extraordinary gains in its retail business during the first quarter, DGSE expects to post a record quarter. Based on these strong results the company intends to accelerate the pace of new stores, building on its success of recent openings. "In the first quarter we enjoyed solid increases in sales and profits, as consumers responded to our new stores better than anticipated. We want to continue executing on our profitable growth strategy while strengthening our brand," said Allison DeStefano, President of DGSE. "We believe with our disciplined approach to site selection, relatively low investment costs and strong new store opening performance, we can profitably expand our store count nationally," added DeStefano. The contemplated store openings are subject to finding suitable locations, negotiate suitable purchase or lease terms, and hiring operating personnel in our target markets and there is no guarantee that we will be able to for our planned expansion in any future period.

08:46 EDT Commvault sees Q1 non-GAAP EBIT margins 20%

08:44 EDT INNOVATE Corp.'s R2 Technologies announces first year commercial milestone - R2 Technologies, a portfolio company of INNOVATE, recently announced two important milestones in the continued development and commercialization of its CryoAesthetic medical devices and technologies. Last week, R2 announced that it has shipped 100 GLACIAL devices to customers globally. R2 customers have performed over 15,000 GLACIAL treatment cycles. R2 also recently announced that data related to GLACIAL Rx was presented during the annual meeting of the American Society for Laser Medicine and Surgery which took place from April 27 to 30, in San Diego, CA. "These important milestones are testaments to the groundbreaking work happening at R2. The team has generated incredibly strong momentum despite the continued impact of the pandemic, delivering 100 devices since GLACIAL Rx's commercial launch just one year ago, and we are thrilled with the overwhelmingly positive customer feedback we have received on the GLACIAL Rx platform. Additionally, having the opportunity to present clinical data at the ASLMS Annual Meeting is an exciting development that underscores the market potential for R2 technologies. We look forward to continuing to support the growth of R2's innovative product pipeline as we seek to drive meaningful value for our stakeholders," said Avie Glazer, Chairman of INNOVATE.

08:43 EDT Expeditors notes financial impact of cyber attack - The company said, "In the first quarter the Company incurred, as a result of our inability to timely process and move shipments through ports, approximately $40 million in incremental demurrage charges, where the Company has direct liability for this obligation. These costs are recorded in customs brokerage and other services expenses. Additionally, in the first quarter, the Company incurred investigation, recovery, and remediation expenses, including costs to recover its operational and accounting systems and to enhance cybersecurity protections. These costs are primarily comprised of various consulting services including cybersecurity experts, outside legal advisors, and other IT professional expenses. The Company also recorded estimated liabilities for potential shipment-related claims. Total amounts recorded for the items above were approximately $20 million and are reported in other operating expenses. The Company does not expect to incur significant capital expenditures as a result of the cyber-attack. The Company may incur additional expenses which could include third-party expenses, incremental information services costs, legal fees, or indemnities to customers or business partners. When the Company's operating systems were down, many customers worked with other providers to meet their logistics needs, resulting in lower shipment volumes in the first quarter for which the financial impact on revenues and operating income cannot be quantified. Such costs and the ongoing impacts from the down time caused by the cyber-attack could have a further material adverse impact on the Company's business, revenues, expenses, results of operations, cash flows and reputation. The Company is unable to estimate the ultimate direct and indirect financial impacts of this cyber-attack."

08:42 EDT Redwire names Al Tadros Chief Technology Officer - Redwire announced the appointment of Al Tadros to Chief Technology Officer . Tadros was most recently serving as Redwire's Chief Growth Officer. This transition significantly strengthens Redwire's technical culture and ability to take on much larger and more complex technical programs, while also giving an opportunity for Michael Gold, Executive Vice President of Civil and Commercial Space, and Dean Bellamy, Executive Vice President of National Security Space, to expand their roles on the executive team. Gold and Bellamy will now lead Redwire's growth strategy in their respective markets and report directly to the Chief Executive Officer.

08:41 EDT Ageagle Aerial Systems reports government demand for eBee TAC UAS - AgEagle Aerial Systems announced that demand for its NDAA-compliant eBee TAC Unmanned Aerial System, UAS, has been increasing with shipments to and training of U.S. and NATO forces in the United States and Europe currently underway. The eBee TAC was the first approved drone to be added to the Department of Defense's Defense Innovation Unit's Blue UAS Cleared List as part of the Blue sUAS 2.0 project. Since the announcement in March 2022, demand for the eBee TAC has been climbing. eBee TAC is available for purchase by U.S. government agencies and all branches of the military on GSA Schedule Contract #47QTCA18D003G. Barrett Mooney, Chairman and CEO of AgEagle, stated, "Participation in industry events such as AUVSI and GEOINT are fueling notable sales interest in the eBee TAC, as well as AgEagle's full line of industry leading drones, sensors and software solutions for both commercial and government use. Moreover, our in-market growth drivers continue to perform well across geographies worldwide. Looking ahead, we intend to remain focused on converting leads into customers and on continued investing in innovation to meet the needs of our expanding global customer base spanning a broad range of industries. All things considered, 2022 could prove to be a watershed year for AgEagle."

08:40 EDT Commvault CEO: Apointment of Merrill as CFO reflects 'deep bench of talent' - Comments taken from Q4 earnings conference call.

08:38 EDT Cloopen forms independent committee to investigate employees irregularities - Cloopen Group Holding announced that it has formed an independent special committee to investigate certain employee misconduct and transaction irregularities. The Company's Board of Directors has formed an independent special committee to oversee an internal investigation of the issues that were raised to the Board's attention by KPMG Huazhen. The Special Committee initially comprises three independent directors of the Board. The Special Committee has been empowered to retain independent advisors, including independent legal advisors and forensic accountants, in connection with the Independent Investigation. During its audit of the Company's consolidated financial statements for the FY21, KPMG raised to the Company's management certain misconduct of several employees of the Company, including fabricating certain documents. In addition, KPMG advised the Company that they identified irregularities relating to certain customers' transactions for previous years. The Company currently expects that the impact from such employee misconduct and transaction irregularities would be 5%-10% of the revenue for the three-month period ended June 30, 2021 and 15%-20% of the revenue for the three-month period ended September 30, 2021. These figures have not been independently verified by the Special Committee or its advisors and are subject to change as the Independent Investigation proceeds. The Company has not concluded on the potential implications on its consolidated financial statements of previous years. The Company will release additional information concerning the Independent Investigation in due course and is committed to taking appropriate measures to improve its internal controls.

08:37 EDT Manhattan announces new machine learning added to Manhattan Active Omni suite - Manhattan Associates announced the latest infusion of machine learning into its Manhattan Active Omni suite to improve the accuracy of delivery date calculations when fulfilling online orders from stores. Manhattan's testing found that this new technology can decrease late deliveries by between 30% and 50%. Manhattan has enhanced its Interactive Inventory offering, part of its industry-leading order management solution, with machine learning to give online shoppers the most accurate and optimized delivery dates in real time. The solution uses the latest technologies to dynamically calculate delivery dates with a precision that is simply not possible using configuration methods.

08:36 EDT Silicon Motion confirms quarterly cash dividend - Silicon Motion Technology confirms its quarterly cash dividend. On October 25, 2021, the Board of Directors of the Company declared payment of an annual dividend of US$2.00 per ADS1, equivalent to US$0.50 per ordinary share, which will be paid in four quarterly installments of $0.50 per ADS, equivalent to US$0.125 per ordinary share. According to the previously announced record and payment dates, the next quarterly installment will be paid on May 26, 2022 to all shareholders of record on May 12, 2022. Our depository bank's DR Books will be closed for issuance and cancellation on May 12, 2022.

08:35 EDT Silicom announces POs for $15M from one of the SD-WAN market's largest vendors - Silicom announced that an existing customer, one of the SD-WAN market's largest vendors, has placed purchase orders, or POs, for Silicom's SD-WAN Smart Platforms in the aggregate amount of $15M with delivery requested during 2022, and that shipments against these POs have already begun. In parallel, the client's forecasts call for equipment valued at more than $25M to be delivered each year for the next several years.

08:34 EDT Village Farms' Pure Sunfarms, NOYA bring Cookies sun-grown flower to Ontario - Pure Sunfarms, a wholly-owned subsidiary of Village Farms International, and NOYA Cannabis announce that Cookies sun-grown flower will be available in Ontario this month. Pure Sunfarms is the licensed producer of record for Cookies sun-grown flower in Canada. "It's an honour to be the sun-grown partner for one of the biggest cannabis brands in the world," said Mandesh Dosanjh, President & CEO, Pure Sunfarms. "Our team knows what it takes to bring out the best in our flower. The Cookies genetics we've grown in our greenhouse have really thrived. We know sun-grown flower is the best flower - and now we get to bring these strains into the light for Cookies consumers to enjoy. They're going to see great genetics, great quality, at great prices."

08:33 EDT Kala announces new commercial, Medicare coverage for EYSUVIS - Kala Pharmaceuticals (KALA) announced that the largest Pharmacy Benefit Manager in the United States has added EYSUVIS 0.25% as a covered brand on its commercial formularies, effective May 1, 2022. This adds 28.5M commercial lives to EYSUVIS coverage, bringing total commercial coverage to 155.3 million lives, or 92% of total commercial lives. Also today, Kala announced that Humana (HUM), one of the largest Medicare health plans in the United States, has added EYSUVIS as a Preferred Brand on its Medicare formularies, effective June 1, 2022. This adds approximately 7M Medicare lives to EYSUVIS coverage, bringing total EYSUVIS Medicare coverage to 14.1M lives, or approximately 30% of all Medicare lives. "We are excited to announce this additional payer coverage, which brings our commercial access to 92% of covered lives and doubles our Medicare Part D coverage. This is an important step toward our goal of securing broad commercial and Medicare access for EYSUVIS and we expect the additional coverage will translate into higher prescription fulfillment rates and accelerated growth," said Todd Bazemore, President and Chief Operating Officer of Kala Pharmaceuticals. "Earlier this year, we secured coverage with several large commercial and Medicare Part D plans and, together with these additions, we have now achieved total EYSUVIS coverage for more than 169 million lives. We continue to engage with other commercial and Medicare Part D health plans and anticipate further formulary additions in 2022."

08:32 EDT MySugarWatch launches physician-focused ads in MIMS - Nemaura Medical announces that its UK licensee, MySugarWatch, as part of a large scale awareness campaign for the Company's sugarBEAT non-invasive continuous glucose monitor, has launched a series of ads in one the UK's preeminent physician and pharmacist education resources, MIMS. MySugarWatch's campaign is targeted to more than 50,000 clinicians as commercialization of sugarBEAT commences. The wider campaign, which also targets a wide variety of media outlets targeting both consumers and professionals, began in April 2022.

08:31 EDT Pliant Therapeutics receives FDA Fast Track designation for PLN-74809 - Pliant Therapeutics has received Fast Track designation from the U.S. Food and Drug Administration, FDA, for the potential treatment of idiopathic pulmonary fibrosis, IPF. PLN-74809, the Company's lead drug candidate, is currently being tested as part of the INTEGRIS-IPF Phase 2a clinical trial. Pliant anticipates topline data from this randomized, double-blind, placebo-controlled trial in patients with IPF, in mid-2022. "The Fast Track designation marks an important step in PLN-74809's clinical development in IPF. It underscores the urgent need for new therapeutic options to address this devastating disease," said Eric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. "We will continue to work closely with the FDA to support the future development of PLN-74809 beginning with data from the Phase 2a INTEGRIS-IPF trial, which is on track for readout in mid-2022."

08:30 EDT Sesen Bio trading resumes

08:29 EDT Tesla to hold 2022 Annual Shareholder Meeting on August 4 in Austin, TX - Tesla will hold its 2022 Annual Shareholder Meeting will be on August 4th in Austin, TX, the company said via Twitter. Reference Link

08:26 EDT Paycor announces release of Paycor Expense Management - Paycor HCM announced the release of Paycor Expense Management, a new solution that simplifies the expense process. The new offering makes it easy for employees to enter expenses for managerial approval, and for payroll specialists to reimburse employees- all through the same system used to process payroll. Paycor Expense Management also allows employees to upload receipts and enter expense data from either their web or mobile devices. "As companies continue to struggle to keep up with shifting workforce dynamics brought on by the continuation of the Covid-19 pandemic and coupled with The Great Resignation, reducing inefficiencies will be key to succeeding," said Ryan Bergstrom, Chief Product Officer at Paycor. "By streamlining time-consuming and manual HR tasks like expense management, we empower leaders to invest more time and resources into developing their teams."

08:25 EDT Seritage Growth Properties signs lease with Amazon in California - Seritage Growth Properties (SRG) and Invesco Real Estate announced Amazon (AMZN) has signed a lease for 123,000 square feet at The Collection at UTC in La Jolla, California, with plans to create more than 700 corporate and tech jobs over the coming years. The Collection at UTC is now 93% leased. The Collection at UTC is a mixed-use project comprising approximately 13 acres and 212,000 square feet of Class A office, retail and restaurant space. Amazon will occupy the entire top two floors. The Collection represents a reimagining of former department store space into a dynamic array of uses and experiences that will define 21st century work and leisure. It is the first step in a multi-pronged vision to activate the broader site for a world class campus that includes life sciences, tech and residential uses.

08:24 EDT Broadcom announces opportunities for solutions with Z16 Mainframe - Broadcom announced expanding opportunities for organizations to gain greater value from the company's advanced AI, security, and hybrid cloud solutions with "Day One" support for IBM's new z16. Broadcom's suite of leading software solutions, services, and unique "beyond code" programs provide clients the advantage they need to succeed in an increasingly challenging business environment. As a member of the z16 Early Ship Program, Broadcom collaborated with IBM to ensure clients can capitalize on the full range of our mainframe software solutions on the new platform to drive progress toward their innovation and business goals.

08:22 EDT Amarin announces publication of new REDUCE-IT data analysis - Amarin Corporation announced the publication in the Journal of the American College of Cardiology of a new REDUCE-IT data analysis further strengthening evidence of the benefits of icosapent ethyl in adult patients most at risk of suffering from a potentially fatal or non-fatal cardiovascular event. This new sub-analysis was led by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women's Hospital, Harvard Medical School, Boston, MA. The patients identified in the new REDUCE-IT sub-analysis had experienced a prior myocardial infarction, commonly called a heart attack, and as previously demonstrated, are therefore at much higher risk of another serious CV event without further intervention. Research has shown that people who have had a heart attack are up to 50% more likely to have another CV event or heart procedure within only one year. The REDUCE-IT Prior MI sub-analysis studied 3,693 patients who had a prior MI within a median of 4.8 years before randomization. Baseline characteristics were similar among patients randomized to icosapent ethyl versus placebo. Icosapent ethyl significantly reduced the primary composite endpoint by 26%, equating to an absolute risk reduction of 5.9%. Total events were significantly reduced by 35% in patients with prior MI who are at high risk of another major event. Icosapent ethyl also led to a 29% reduction in the key secondary composite endpoint of CV death, non-fatal MI, or non-fatal stroke. Rates of sudden cardiac death and cardiac arrest were also significantly reduced, showing 40% relative risk reduction and 56% relative risk reduction, respectively. The safety of icosapent ethyl among patients with prior MI was consistent with the main study findings in the entire population, with increased rates of atrial fibrillation and of minor bleeding, though no significant increase in major bleeding. These data included both prespecified and post hoc analyses. It Is important to note that the exploratory nature limited the post hoc analysis. REDUCE-IT was not powered for subgroup analyses and all P-values should be considered hypothesis generating. The landmark REDUCE-IT cardiovascular outcomes study, published in New England Journal of Medicine in 2019, enrolled 8,179 patients for a median of 4.9 years, who were required to be treated with statins and other standard of care therapies. All patients had controlled low-density lipoprotein cholesterol, elevated triglyceride levels, and either established CVD or diabetes with other cardiovascular risk factors. Multiple trials have shown that statin therapy delivers a significant risk reduction of 25% to 35% for CV events, but this leaves a residual risk, beyond LDL-C treatment, of 65% to 75%. The high level of remaining risk strongly suggests the need for additional cardioprotective measures to help patients avoid a potentially life-changing or lethal CVD event by reducing the underlying CV risk beyond LDL reduction.

08:20 EDT Skylight Health executes agreement to acquire NeighborMD - Skylight Health announces the execution of a definitive agreement to acquire NeighborMD, NMD, which will close concurrently with a debt facility of $20M that the Company has arranged with a New York-based lender. Based in central and southern Florida, NMD operates 9 owned practices offering primary care services to over 5,000 lives. At the expected close of the acquisition, all key leadership and operational teams will continue with Skylight. Total consideration for NMD will be $8M paid in cash at closing. In conjunction with the closing of NMD, the Company has also arranged a $20M debt line facility with a New York based credit lender that will close at the same time as the closing of the acquisition. Terms of the facility will allow for the Company to draw down $10M to fund the NMD acquisition including working capital to support integration costs and operating expenses. "We are excited to be able to soon welcome NMD and its team to Skylight and bring significant growth and opportunities to our organization and shareholders in less than a year of our NASDAQ debut," said Prad Sekar, CEO of Skylight Health. "With the recent announcement of our JV with CHS, this acquisition will significantly accelerate our entry into full risk in 2022, as originally planned for 3-5 years out. The experience, knowledge, and capabilities that will join Skylight from the team at NMD and our JV, allow us to see a pathway for significant growth organically, and validation for our disciplined acquisition strategy."

08:19 EDT Sondrel deploys Arteris IP for next-generation multichannel automotive SoC - Sondrel and Arteris IP announced that Sondrel is adopting FlexNoC interconnect IP in its next generation of advanced driver-assistance systems architecture. The onchip-interconnect was selected for its configurability and performance. The product enables the SFA 350A multi-channel automotive vehicle IP platform requirements. FlexNoC supports the ability to design the NoC to match the performance of IP blocks to ensure that data flows at the right speed in, out and around the SoC. It enables designers to quickly design and verify a chip that precisely meets the customer's silicon specifications on time and within budget.

08:18 EDT Foothills Exploration provides Wind River Basin update - Foothills Exploration is pleased to announce an operations update for Q1 2022. On March 9, 2022, the Company acquired an additional 1,960 acres of State leases from the State of Wyoming, to provide additional potential drilling locations in the Wind River Basin. This acquisition brings the Company's total acreage in the Wind River Basin up to 20,847 acres. The importance of this lease acquisition is that we can expedite a drilling permit on State lands. The Company is still actively pursuing a JV partner and has had discussions with other local operators about sharing the cost of rig mobilization for its proposed drilling program. The Company, through its direct subsidiary, Anaconda Energy, LLC, closed on the acquisition of two small oil and gas operators in the Illinois basin on December 28, 2021. The acquisition included all of the assets of the operating companies, including working interests held in certain oil and gas wells and leases and five percent overriding royalty interest in certain leases and wells. The acquisition also came with 20 oil wells, of which 9 can be worked over. During Q1 2022, the Company performed workover operations on three of the wells, which successful generated a 75% increase in production for total operations. The asset is on track to pay out within ten months. In Q1 2022, the Company's Illinois Basin properties generated $247,712 in total gross revenues, with net revenues of $107,297 attributable to Anaconda and its subsidiaries. The Houser-Sears #4 well recompletion in the Aux Vases formation proved successful with the well's initial production coming in at around 33 barrels of oil per day, which has stabilized at around 7 BOPD. Anaconda Energy has a 50% working interest in the proposed well on the Houser-Sears leasehold. The parties plan to drill a new well to a proposed depth of 3,500 feet in the month of June. This infield drilling location is in a stacked-pay environment with the potential to produce from several pay zones. The primary objectives are the Aux Vases Sand, Upper McClosky Limestone and McClosky Dolomites. The secondary objectives are the St. Louis Lime and Salem Lime. The well is expected to pay back within 180 days of initial production. The Company signed a participation agreement to participate in 50% of the rework operations of the Mark Heat #4 well. The objective is to frac the Aux Vases formation with the expectation of a 30 BOPD initial production. The rework operation is scheduled for the end of Q2 2022. The Company realized total revenues of $80,529 in January and February 2022 from its 21.7% non-operated working interest in two EOG-operated horizontal wells located in the Uintah Basin of Utah. The Company closed on the acquisition of six wells in Carter and Garvin counties in Oklahoma. Three of the six wells are currently producing and the other three are return to production candidates. The Company's New Energy Ventures division is currently in the research phase of its evaluation into the production of green energy by repurposing abandoned oil and gas wells into geothermal wells and also producing hydrogen from abandoned wellbores using emerging new technologies.

08:14 EDT Beam Global hits 'record' first quarter deliveries - Beam Global announced the highest number of system deliveries in the first quarter of any year in the company's history. Q1 was also the second biggest quarter for deliveries in Beam's history following the record fourth quarter 2021. "Q1 has historically been a slower quarter for us but not this year. The momentum we built in 2021 continues with a first quarter record start in deliveries for Beam Global," said Desmond Wheatley, CEO of Beam Global. "The 2021 historic highs in new orders set the pace for record revenue and deliveries in 2021 but also, importantly, enabled us to continue that pace and deliver record results in the first quarter of 2022 as our investments in sales, operations and manufacturing deliver returns. With pipeline also at a new high, we see no sign of this abating, boding well for continued momentum and growth for the year."

08:13 EDT ProKidney highlights key registrational program elements supporting REACT - ProKidney highlighted the key registrational program elements supporting development of its autologous cell therapy REACT for diabetic CKD. The design of the Phase 3 program for REACT is a result of the company's consultation with the Food & Drug Administration, FDA, for this first in class cellular therapy being developed to restore kidney function in patients with CKD. With the grant of RMAT designation for REACT, the FDA is providing ProKidney in-depth guidance on the REACT registrational program. Collectively, this comprehensive development plan is designed to support North American and European marketing with regulatory submissions targeted for late 2025 or early 2026. FDA Confirms ProKidney's Design of The Phase 3 Clinical Program for REACT: The registrational clinical program is designed to generate efficacy and safety data in two randomized, sham-controlled, blinded studies with a three-component primary endpoint under a Time-to-Event design. Study subject demographics will be consistent with previous trials involving REACT. The robust safety profile of REACT after two injections in the same kidney in clinical studies thus far supports an effort to enhance efficacy potential by injecting subjects in both kidneys in the Phase 3 program. Study subjects in the treatment arm will undergo a kidney biopsy and then be injected in each kidney once with a three-month interval in between injections. Specifically, the primary composite endpoint for this Phase 3 clinical program is the time from the first injection to the earliest of: At least 40% reduction in estimated glomerular filtration rate, which is a measure of how well the kidneys are working; eGFRless than15mL/min/1.73m sustained for 30 days and/or chronic dialysis, and/or renal transplant; or Death from renal or cardiovascular causes. In addition to the primary endpoint, a set of key secondary endpoints will be included to evaluate trends in proteinuria, quality of life, other kidney associated laboratory parameters, and other metrics. FDA Accepts ProKidney's Proposed Matrix Potency Assay for REACT: In providing guidance for a commercial-ready manufacturing program, the FDA accepted ProKidney's proposed matrix potency assay characterizing the progenitor cell population in REACT and cytokine profile supportive of the REACT mechanism of action. Furthermore, the FDA accepted ProKidney's proposal for a long-term 5-year clinical follow-up program for all REACT injected patients, to be enrolled with patients who have previously received REACT injections in one or both kidneys. This long-term follow-up program could provide robust evidence in support of premium pricing and product durability for REACT. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III.

08:13 EDT Hepion Pharmaceuticals enters clinical collaboration with HepQuant - Hepion Pharmaceuticals announced that it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for evaluating liver function and health in patients with chronic liver diseases. Hepion will incorporate the HepQuant 'SHUNT' test into a dedicated Phase 2b clinical trial in presumed NASH F3 subjects, initiating in Q3 of this year. Hepion will evaluate three doses of rencofilstat in 60 presumed NASH F3 subjects using the HepQuant SHUNT test along with numerous NASH biomarkers collected over four months of once daily oral dosing. HepQuant's SHUNT test may provide a sensitive measurement of hepatic function and is designed to provide detailed information on the role rencofilstat plays in improving the liver health in NASH subjects with advanced fibrosis. This trial will supplement the Company's larger 12-month Phase 2b NASH clinical trial in biopsy-proven F2/F3 NASH subjects, which will begin in Q3 of this year; and will run concurrently with Hepion's ongoing Phase 2a clinical trial for hepatocellular carcinoma.

08:12 EDT Teva says biosimilar pipeline 'progressing nicely' - Says 13 biosimilars currently in development. Says "hopeful" for opioid settlement for all states by end of year. Targeting net debt/EBITDA less than 3x by end of 2023. Comments taken from Q1 earnings conference call.

08:12 EDT STMicroelectronics publishes 25th annual sustainability report - STMicroelectronics releases its 25th annual sustainability report detailing 2021 performance and achievements. Collaborating with customers and partners, ST creates innovative technologies that bring an important contribution to overcome the environmental and social challenges of the planet today. "This is our 25th annual report, a significant milestone after the pioneering efforts of ST in this field. In 2021 we continued to achieve strong results across all key sustainability metrics, including the initial steps of our path towards carbon neutrality in 2027. We are determined to continue to do more and to accelerate our overall sustainability efforts to create technology for a sustainable world, in a sustainable way, and to generate long-term value for our people and all stakeholders," said Jean-Marc Chery, President and CEO, STMicroelectronics. In 2021 ST has been actively working, through a collaborative approach, on its sustainability commitments and programs to create a healthier, safer, and more inclusive environment for people and communities and to create profitable growth. ST's continued efforts across many areas, detailed in this report, were recognized again in 2021, by inclusion in the DJSI World and Europe indexes, as well as in other key ESG rankings and international certifications.

08:11 EDT Sabre provides 2025 financial targets at possible bookings recovery scenarios - At greater than 80% bookings recovery, sees 2025 adjusted EBITDA greater than $900M and free cash flow greater than $500M. At greater than 100% bookings recovery, sees 2025 adjusted EBITDA greater than $1.1B, with free cash flow greater than $700M. At greater than $120% bookings recovery, sees 2025 adjusted EBITDA greater than $1.3B, with free cash flow greater than $900M.

08:10 EDT Metals Company announces data on manganese silicate product - TMC the metals company revealed that recent studies conducted by SINTEF, an independent research institution based in Norway and retained by TMC to undertake test work and value-in-use analysis, confirm that TMC's nodule-derived manganese silicate product has similar properties to manganese ores and is suitable for further processing into key steel-making feedstocks like silicomanganese alloy. While much of the interest in polymetallic nodules has been driven by surging demand for nickel, cobalt and copper for the clean energy transition, the development of TMC's vast nodule resource could prove transformational for manganese markets with the potential to become an abundant, accessible source of the important base metal with significant opportunities to reduce lifecycle ESG impacts compared to land-based mining. Investigators at SINTEF's facilities in Norway set out to assess whether TMC's manganese silicate product could meet the specifications required by potential customers in the steelmaking value chain. SINTEF's report finds that TMC's nodule-derived Mn silicate has a high grade but lower oxidation state compared to land-based ores, which can potentially reduce the energy intensity - and overall cost - of SiMn production. For a manganese industry accustomed to slim single-digit margins, SINTEF's findings point to the potential for TMC's nodule-derived manganese product to improve the economics of alloy production while also reducing the industry's carbon footprint as compared to manganese from traditional Mn ore. To reach the conclusions, SINTEF carried out high-temperature reduction experiments simulating conditions in SiMn production using TMC's manganese silicate product, together with metallic iron, quartz, coke and CaO additions, and then characterized and compared the resultant products with literature data and industry knowledge. The metallurgists found that the feed mixture reacted at a similar rate to that of traditional manganese sources and that pre-reduction, which contributes heavily to CO2 emissions, could be fully avoided. Results also show that the SiMn was produced within typical specifications and with acceptable levels of impurities. For the comparative economic valuation, SINTEF employed mass and energy balance calculations on various feed scenarios with unit cost estimates provided by TMC. The evaluation concluded that the production of SiMn with TMC's product as feed can lower costs, as the product has up to 17.6% higher value than traditional ores, based on their manganese content. Comparisons to conventional Manganese Rich Slag feeds were also conducted with similar outcomes. In 2021, over half of the 20 million tonnes of manganese ore produced globally went into the production of silicomanganese alloy for the steel industry, which is expected to grow at ~3.5% per annum. The resource requirements of such growth are particularly acute in developing states like India, the world's second largest steel producer, which is targeting a three-fold expansion in steel manufacturing capacity by 2030. In March, TMC announced that it signed a Memorandum of Understanding with Epsilon Carbon, a leading developer of graphite materials for lithium-ion battery anodes and India's only company to be backward-integrated into the steel industry, for the completion of a pre-feasibility study for a commercial-scale deep-sea nodule processing plant in India. The companies are targeting production of more than 750,000 tonnes per annum of manganese silicate grading around 42% Mn, as well as more than 30,000 TPA of an intermediate nickel-copper-cobalt matte product used for active cathode material for Nickel Manganese Cobalt and other nickel-rich battery cathode chemistries. With a potential production capacity of 2.9 million tonnes per annum of manganese silicate, TMC's NORI-D Nodule Project could feasibly become a major source of manganese feedstock for India and beyond. Since 2020, TMC has been undertaking extensive onshore pilot processing work to convert polymetallic nodules into high-grade critical metals. In September 2021, the Company announced that it had successfully utilised a custom process derived from conventional nickel flowsheets to segregate the base metals contained in nodules into an alloy comprised of high-grade battery metals, as well as the manganese silicate output analysed by the team at SINTEF. The findings of the SINTEF report and related work by TMC will be presented at the upcoming Conference of Metallurgists being held August 21 to 24 in Montreal, Quebec.

08:10 EDT LianBio partner Tarsus Pharmaceuticals announces data from trial of TP-03 - LianBio's (LIAN) partner, Tarsus Pharmaceuticals (TARS), yesterday announced that TP-03 met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal Phase 3 trial with a favorable safety profile, reinforcing its potential to resolve Demodex blepharitis, a highly prevalent eyelid disease. With these results, Tarsus plans to submit a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, in the second half of 2022. "We congratulate our partner Tarsus on continuing to demonstrate clinically meaningful and statistically significant disease resolution in the second pivotal trial of TP-03," said Yizhe Wang, Ph.D., chief executive officer of LianBio. "These data reinforce TP-03's potential to become the standard of care for the treatment of Demodex blepharitis. We estimate there are approximately 43 million patients with Demodex blepharitis in China, and there are currently no therapies approved in China for these patients. We look forward to initiating our planned Phase 3 study of TP-03 in China." LianBio licensed rights from Tarsus in March 2021 for the development and commercialization of TP-03 in Greater China. LianBio expects to initiate a registrational Phase 3 clinical trial of TP-03 in the second half of 2022 to support regulatory approval in China.

08:07 EDT Capstone Green Energy receives order for two microturbine systems - Capstone Green Energy announced that E-Finity Distributed Generation, Capstone's exclusive distributor for the Mid-Atlantic, Southeastern United States and the Caribbean, has secured an order for two Capstone C1000S microturbine systems for a government water authority in the Caribbean. The systems will provide emergency standby power to several pumping stations throughout the remote island community. The 2 megawatt, or MW, system is scheduled to be commissioned towards the end of calendar year 2022.

08:07 EDT PolarityTE enrolls first patient in Phase III pivotal study evaluating SkinTE - PolarityTE announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers, or DFUs, entitled "Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE," or "COVER DFUs." COVER DFUs will enroll up to 100 subjects at up to 20 clinical sites in the United States. Subjects will be randomized to one of two treatment groups, receiving either SkinTE plus the standard of care or the SOC alone. The primary endpoint is the incidence of DFUs closed at 24 weeks. Secondary endpoints include percent area reduction at 4, 8, 12, 16 and 24 weeks; improved quality of life, including social isolation, depression, odor, improved function, ambulation, and return to activities based on changes in wound quality of life; and new onset infection of the DFU requiring treatment with topical and/or systemic antibiotics.

08:06 EDT Schnitzer purchases operating assets of Encore Recycling , no terms - Schnitzer Steel announces that it has purchased the operating assets of Encore Recycling in the greater Atlanta Metro area. The acquisition closed on April 29th and encompasses two full-service recycling facilities, including a metal shredding operation and recycled auto-parts center. Founded in 2013, Encore has a well-established customer-focused business that purchases and processes end-of-life vehicles, appliances, and additional ferrous and nonferrous materials from local recycling companies and industrial, commercial, and individual customers. Encore sells its recycled products to steel mills and foundries throughout the Southeast, the fastest growing steel and industrial manufacturing region in the country. The acquisition of Encore's assets follows Schnitzer's 2021 purchase of eight recycling facilities from Columbus Recycling and expands the Company's Southeastern regional footprint to 24 recycling facilities across Alabama, Georgia, Kentucky, Mississippi, and Tennessee. The integration of the Encore assets into the Schnitzer operating model will enable the Company to provide additional products, services, and logistics solutions to customers and suppliers across the Southeast. In 2021, the Encore facilities processed approximately 90,000 ferrous tons, 14 million nonferrous pounds, and 20,000 end-of life vehicles. In furtherance of its commitment to sustainable operations, Schnitzer plans to make capital and other investments at the acquired facilities, including for environmental projects and programs such as a shredder enclosure and emission control system, stormwater infrastructure upgrades, and implementation of a U.S. Environmental Protection Agency approved refrigerant recovery management program.

08:05 EDT Everi Holdings acquires Intuicode Gaming - Everi Holdings announced that it has acquired Intuicode Gaming Corporation, a privately owned game development and engineering firm focused on Historical Horse Racing, or HHR, games. In 2021, Intuicode generated over $10M in annual revenue from the sale of gaming machines and recurring participation revenue from game theme placements at HHR locations throughout the United States. Intuicode and its experienced HHR game development team provide Everi with additional HHR expertise that will help the Company accelerate its entry into and growth in the expanding HHR market. The acquisition cost includes an initial payment of $12.5M, with two additional payments based on future revenue to be made on each of the first and second anniversaries of the acquisition's closing in 2023 and 2024. Total consideration is expected to be $22M-$27M, and Everi expects to fund the purchase price from existing cash on hand and future cash flow.

08:03 EDT Home Depot announces $150M venture capital to improve customer experience - The Home Depot announced Home Depot Ventures, a venture capital fund created to identify, fund and partner with early-stage companies to accelerate emerging technologies that aim to improve the customer experience. The $150M fund aims to invest in companies that advance The Home Depot's ability to provide a seamless interconnected shopping experience.

07:59 EDT BIO-key announces upgrades to BIO-key MobileAuth - BIO-key International announced upgrades to BIO-key MobileAuth, a multi-factor authentication mobile app that integrates the power of IBB across multiple authentication modalities, allowing customers to build a more complete MFA strategy. These methods include palm scanning and facial recognition. In addition to the newest IBB-powered modalities, MobileAuth supports device-based biometric authentication methods including Apple Face ID, Touch ID, and Android Biometrics, as well as support for push token authentication. These enhancements make biometrics even easier for customers to deploy across a wider set of use cases and further consolidate their authentication and security solutions.

07:53 EDT Western Digital jumps 10% to $59.17 after Elliott urges full strategic review

07:52 EDT Daseke sees 2022 capital expenditures $145M-$155M - "We are pleased with the continued operational execution and the financial results delivered by our team," said Jason Bates, Chief Financial Officer of Daseke. "As a reminder, Daseke is unique in that we don't have the same spot rate or dry van retail exposure of many of our public peers. We are a contractually-based, industrial-oriented business, focusing on niche, defensible end markets - which are all continuing to exhibit strength as well as an ongoing supply / demand imbalance. These factors have enabled us to capture strong rates, drive double-digit revenue growth and expand profitability. While we are facing inflationary cost pressures in various areas, including driver recruitment and retention, operations and maintenance and insurance expenses, we have been able to maintain our margins through a combination of rate strength and contributions from our ongoing transformation initiatives. As we look further ahead, we are re-affirming our full year 2022 financial outlook provided last quarter. Although we are mindful of the various macroeconomic events and factors facing our industry, we remain confident that through our transformation initiatives, our disproportionately high contract versus spot market exposure, combined with our unique end-market alignment, which carries higher barriers to entry, we are uniquely positioned to generate improved revenue and profitability performance in 2022. We have observed ongoing delays in receiving new equipment as the supply chain disruptions persisted throughout the first quarter of 2022. Given these challenges in sourcing new equipment from our OEM's we are reducing our full year net capital expenditures outlook, now anticipating a range of $145 to $155 million."

07:47 EDT Baxter boosts dividend 3.5% to 29c per share - Baxter International announced an increase in the company's quarterly cash dividend to a rate of 29c per share of common stock. This represents an approximately 3.5% increase over the previous quarterly dividend rate of 28c per share. Baxter's Board of Directors declared the dividend payable on July 1 to stockholders of record as of June 3. The indicated annual dividend rate is now $1.16 per share of common stock. "Baxter continues to advance its lifesaving Mission and deliver value for shareholders amid an unprecedented healthcare landscape," said Jose E. Almeida, chairman, president and chief executive officer. "With our dedicated employees, diverse portfolio and disciplined approach to capital allocation, we are pleased to increase our dividend for the seventh straight year. We will continue to focus on advancing innovation, accelerating growth and realizing the potential of our Hillrom acquisition to benefit patients, caregivers, investors and the many other stakeholder communities that depend on us."

07:45 EDT Penske Automotive acquires Terry Lee Hyundai and Genesis - Penske Automotive announced that it has acquired Terry Lee Hyundai and Genesis of Noblesville, Indiana, increasing the company's presence in the Indianapolis metropolitan market. The acquisition is expected to generate annualized revenue of $80M. The addition of the Hyundai and Genesis dealerships brings total expected acquired annualized revenue in 2022 to approximately $745M.

07:43 EDT Distributors agree to $518M opioid settlement With Washington state - AmerisourceBergen (ABC), Cardinal Health (CAH) and McKesson (MCK) announced that they have reached an agreement with the Washington Attorney General, under which the distributors will pay up to $518Mn to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with Washington's allocation under the previously announced comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities, as well as certain attorneys' fees and costs. Upon effectiveness of the settlement, the State of Washington will dismiss the lawsuit that is currently being tried. The agreement is subject to certain contingencies, including the rate of subdivision participation. The terms of the agreement with the State of Washington are consistent with the comprehensive settlement agreement, which became effective on April 2. While the companies strongly dispute the allegations made in the plaintiffs' complaints and during trial, they believe that resolving all of the litigation filed by the State of Washington and its political subdivisions will further the companies' goal of achieving broad resolution of governmental opioid claims while delivering meaningful relief to communities across the United States that have been impacted by the opioid epidemic.

07:42 EDT Qualys, White Tuque partner to bolster cybersecurity offerings - White Tuque announced its partnership with Qualys Inc. to add its Vulnerability Management, Detection and Response solution into its service offerings.

07:40 EDT Gamesquare Esports, Complexity Gaming expand Army MWR partnership - GameSquare Esports and Complexity Gaming are pleased to announce an extension of the U.S. Army Installation Management Command's Family and Morale, Welfare and Recreation to host a series of tournaments designed for active duty army soldiers, army national guard, army reserve, & active duty military stationed on army joint bases. Complexity and the Army MWR initiated their partnership in June 2019 and have renewed the partnership annually to deliver longer tournaments to more active-duty soldiers. The 2022 edition of the Soldier Showdown will take place between May 28, 2022, and Oct 29, 2022, and participation is expected to increase by more than 50%, year-over-year. As highlighted in our recently published Letter to Shareholders, management intends to offer customers more choice and to add sponsors and brands across our group of businesses throughout 2022.

07:39 EDT Draganfly first medical response drone now deployed in Ukraine - Draganfly announced that the Company, in partnership with Coldchain Delivery Systems has successfully completed deployment and training of its first Medical Response Drone to Revived Soldiers Ukraine, RSU. Draganfly's initial Medical Response Drone was received by Iryna Vashchuk Discipio, President of RSU, and members of her staff, including pilots, at a facility in Poland on May 1, 2022. The drone was then transported to Ukraine, where the Company's experienced pilots conducted virtual training with RSU's drone operators. Draganfly's Medical Response Drone is equipped with the Company's temperature-managed Medical Response Payload Box, which can transport up to 35 pounds of temperature-sensitive medical supplies, including blood, pharmaceuticals, insulin/medicines, vaccines, water, and wound care kits. "The crisis across Ukraine continues to create challenging conditions for emergency crews trying to provide aid to those in need. Our Medical Response Drone and subsequent drone solutions will help RSU effectively access hotspots and deliver crucial medical supplies and equipment to affected Ukrainians," said Cameron Chell, CEO of Draganfly.

07:38 EDT Entourage Health reaffirms preliminary 2021 revenue C$55.2M - Entourage Health announced it will defer its fourth quarter and full-year 2021 press release and conference call previously scheduled for May 3, 2022, to coincide with its projected first quarter 2022 financial results, expected on or before May 31, 2022. The deferral is a result of the Company's new external auditors advising they were not able to complete required procedures and issue an audit opinion on May 2, 2022 in time to support the Company's management conference call on May 3, 2022 as previously expected, in respect of the Company's financial statement for the year ended December 31, 2021 and the related management's discussion and analysis. Entourage further advised it will file its fourth quarter and full-year 2021 financial results in the coming days, with filing timing to be provided once confirmed by auditors. Additionally, filing and conference call details for first quarter 2022 will be provided in a subsequent announcement. Entourage also reaffirmed that its previously reported full-year 2021 record preliminary unaudited total revenue improved slightly and is now $55.2M together with preliminary gross margins of 7.0%. In accordance with Entourage's Trading Policy, directors, officers, and other insiders of the Company are currently restricted from trading in the Company's securities until after it files its full-year 2021 financials. The Company expects the trading window to open subsequent to the filing of first quarter 2022 financial results, expected by no later than May 31, 2022.

07:37 EDT CME Group reached ADV of 20.8M contracts in April, up 26% y/y - CME Group reported its April 2022 market statistics, showing average daily volume increased 26% to 20.8M contracts during the month.

07:34 EDT Lindblad Expeditions is not providing a FY22 outlook - The company said, "The COVID-19 pandemic has had, and will continue to have, a significant impact on the Company's financial position and results of operation. Given the continued uncertainty around the COVID-19 pandemic, the Company is not providing a full year outlook regarding results of operations at this time and will update its expectations when it has more clarity around the timing and extent of future operations."

07:33 EDT Harmony Biosciences provides clinical development update - Initiated a Phase 3 clinical trial to evaluate the efficacy and safety of pitolisant in adult patients with Idiopathic Hypersomnia. Enrollment continues in the Prader-Willi Syndrome and Myotonic Dystrophy studies. We anticipate topline data from the Phase 2 proof-of-concept trial in PWS in the second half of 2022 and DM1 topline data in 2023. For HBS-102, our early-stage asset, we are on track to begin a preclinical proof of concept study in PWS later in 2022.

07:29 EDT OTC Markets acquires Blue Sky Data assets for $12M - OTC Markets Group announced that it has completed the previously announced acquisition of assets from Blue Sky Data Corp, a leading provider of equity and debt compliance data regarding state "Blue Sky" securities rules and regulations. Through enhancements to its existing Blue Sky data offering, this acquisition will allow OTC Markets to improve its value proposition and expand its subscriber base. The resulting product will provide a comprehensive view of Blue Sky secondary trading compliance data, delivered in an efficient format for broker-dealers, financial advisors, public companies, and regulators. The acquisition includes substantially all of the assets of Blue Sky Data Corp, including customer contracts and intellectual property. The consideration was approximately $12 million in cash.

07:25 EDT Telesat Holdings announces $30.65M Funded Space Act Agreement from NASA - Telesat Government Solutions, subsidary of Telesat (TSAT), announced a $30.65M Funded Space Act Agreement from the National Aeronautics and Space Administration, NASA, as a partner for its Communications Services Project, CSP. Since NASA plans to decommission its owned and operated Tracking and Data Relay Satellite, TDRS, system in the coming years, the agency's CSP will evaluate commercial SATCOM networks' feasibility to reliably support future near-Earth missions. Under the agreement, Telesat Government Solutions will demonstrate Telesat Lightspeed's future space-to-space relay capabilities. As part of the initiative, Telesat Government Solutions intends to partner with Planet Labs PBC (PL) to develop a space-based RF terminal hosted on two Earth observation spacecraft. Once in orbit, Telesat Government Solutions will demonstrate Ka-band, high throughput transmission from the space-based RF terminals to Telesat operated satellites flying at a higher altitude, as well as mesh, space relay connectivity between the optically-linked Low Earth Orbit satellites before downlinking data to representative NASA operation centers. "Space Relay services via the advanced Telesat Lightspeed architecture provide a compelling value proposition for NASA and other government agencies, and we are excited to pioneer this promising and high-growth market," said Tom Eaton, President of Telesat Government Solutions. "NASA's collaboration with the industry has been most impressive as they aim to leverage commercial sector investment and innovation to meet their future near-Earth communications requirements."

07:24 EDT Biogen has begun search for new CEO - Biogen announced that it has begun a search for a new Chief Executive Officer. Michel Vounatsos will continue to serve as CEO and on the company's board of directors until his successor is appointed. Vounatsos, who has served as the company's CEO since his appointment in January 2017, said: "It has been an honor to lead this outstanding company during such a challenging period and to work closely with so many dedicated and talented colleagues. I am very proud of Biogen's unparalleled capabilities in neuroscience, a complex field with tremendous unmet medical need, and of the novel medicines and benefits we have brought to patients. I want to thank the Board of Directors and my colleagues for their support during this period. I will be leaving at a time of promise for Biogen, with noteworthy potential for value creation, and I look forward working with my successor through a smooth transition."

07:24 EDT BioXcel Therapeutics announces first patient dosed in TRANQUILITY II study - BioXcel Therapeutics announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the Company's proprietary, orally dissolving thin film formulation of dexmedetomidine, for the acute treatment of agitation in patients with Alzheimer's disease, AD. The pivotal Phase 3 TRANQUILITY program includes two studies, TRANQUILITY II and TRANQUILITY III, which are designed to evaluate the safety and efficacy of BXCL501 in adults 65 years and older in assisted living or residential facilities and nursing homes. Robert Risinger, M.D., Chief Medical Officer of BioXcel Therapeutics said, "We believe the recent FDA approval of BXCL501 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults has laid a strong foundation for pursuing this Alzheimer's-related agitation program to potentially address this debilitating symptom for patients. Importantly, we are also expanding TRANQUILITY II to more than 10 clinical trial sites in the U.S. and with no current FDA approved treatments for agitation associated with this disease, we are making strong and swift efforts to potentially bring BXCL501 and its proven ability to address agitation to this large market."

07:23 EDT Compass Pathways announces data on COMP360 psilocybin therapy - COMPASS Pathways announced that positive data demonstrating the potential of COMP360 psilocybin therapy in anorexia nervosa and severe treatment-resistant depression has been presented at the Society of Biological Psychiatry Annual Meeting in New Orleans, from two investigator-initiated studies.The first study looked at the safety and efficacy of COMP360 psilocybin therapy in patients with severe treatment-resistant depression, with a single 25mg dose, and was run by Dr Scott Aaronson at Sheppard Pratt, Baltimore. The researchers found that 58.3% of the participants had maintained response criteria, for the Montgomery-Asberg Depression Rating Scale, MADRS, at 12 weeks after COMP360 psilocybin administration, and a quarter had maintained remission. There was no increase in the suicidality score based on the MADRS, and no serious adverse events were reported throughout the study. The second study investigated the safety, efficacy, and tolerability of COMP360 psilocybin therapy in patients with anorexia nervosa, with a single 25mg dose, and was conducted by Dr Walter Kaye at the University of California San Diego School of Medicine. 30% of participants experienced clinically significant reductions in eating disorder psychopathology at the 1-month follow up, and 40% experienced clinically significant reductions at the 3-month follow-up. Participants demonstrated statistically significant reductions in shape concerns at the 1-month follow-up, and statistically significant reductions in eating concerns at the 3-month follow-up. Changes in weight concerns were approaching statistical significance. COMP360 psilocybin therapy was well-tolerated and 90% of participants found the experience to be meaningful and therapeutic. No serious adverse events were reported.

07:21 EDT Heat Biologics completes name change to NightHawk Biosciences - Heat Biologics (HTBX) / NightHawk Biosciences (NHWK) announced that it has completed its name change from Heat Biologics to NightHawk Biosciences to better reflect the Company's evolution. In connection with the name change, the Company's ticker will change to "NHWK," effective today, May 3, 2022. The name and symbol changes do not affect the Company's share structure or the rights of the Company's shareholders, and no further action is required by existing shareholders. Jeff Wolf, CEO of Nighthawk, commented, "The NightHawk brand better reflects our evolution towards a fully integrated ecosystem, designed to efficiently move drugs from discovery through commercialization. The NightHawk ecosystem includes an expanded development pipeline, new biodefense capabilities and enhanced manufacturing capabilities. As a result, we have organized the Company around five key subsidiaries: Skunkworx Bio, Heat Biologics, Pelican Therapeutics, Elusys Therapeutics and Scorpion Biological Services. NightHawk is laser focused on addressing key industry challenges, including the slow pace and high cost of new drug development through a fully integrated ecosystem of drug discovery, preclinical testing and manufacturing. We look forward to progressing these efforts under the NightHawk banner."

07:20 EDT Rockwell Automation board authorizes additional $1B for share repurchases

07:18 EDT Wellbeing Digital appoints Michael Ho medical director of MindScape in Houston - Wellbeing Digital Sciences announce the appointment of Dr. Michael Ho as the new Medical Director of the MindScape Ketamine & Infusion Therapy Clinic in Houston, Texas, effective May 2, 2022. MindScape's former medical director, Dr. Quang Henderson, is retiring after his tenure since founding the Clinic in 2018. Michael Ho serves as the director of Safe Sleep Anesthesia in Houston, Texas.

07:16 EDT Aecom selected by City of Austin's ATD - AECOM announced it has been selected by the City of Austin's Transportation Department, or ATD, to continue serving as engineering consultant augmenting ATD's existing workforce. AECOM will deliver comprehensive engineering design, review, and coordination with City of Austin transportation staff, guided by the priorities of ATD to provide an accessible and reliable transportation network that meets the community's diverse needs. AECOM has served as ATD's selected consultant in this role since 2018. The staff augmentation services provided by AECOM will help ATD secure engineering assistance to accomplish its multimodal transportation and infrastructure improvement objectives, which include maintaining mobility, increasing person throughput, responding to citizen needs, managing congestion and demand, and improving safety.

07:15 EDT Truist Financial acquires Long Game, terms undisclosed - Truist Financial announced it has acquired Long Game, the gamified finance mobile app. Truist will leverage Long Game's technology to help its clients build long-term financial wellness and advance its purpose to inspire and build better lives and communities. As part of the acquisition, Long Game's engineers, designers and business leaders will join Truist's Innovation team. Long Game Co-founder and CEO Lindsay Holden will lead a team of engineers, product managers and designers responsible for technology innovation and development of new client-centric solutions. The team will be based in San Francisco, California.

07:12 EDT LGI Homes sees 2022 average sales price per home closed $335,000-$350,000 - Subject to the caveats in the Forward-Looking Statements section of this press release, the Company updates its prior full year 2022 guidance. The Company now believes that its average sales price per home closed will be between $335,000 and $350,000, its gross margin as a percentage of home sales revenues will be between 27.0% and 29.0% and its adjusted gross margin as a percentage of home sales revenues will be between 28.5% and 30.5% with capitalized interest accounting for substantially all the difference between gross margin and adjusted gross margin as a percentage of home sales revenues.

07:08 EDT Talos Energy, Chevron, Carbonvert announce MOU for expanded JV - Talos Energy (TALO), through its Talos Low Carbon Solutions division, Carbonvert, and Chevron U.S.A., through its Chevron New Energies division, announced a memorandum of understanding for an expanded joint venture to develop the Bayou Bend CCS offshore carbon capture and sequestration hub currently held by Talos and Carbonvert. In 2021, a joint venture between Talos and Carbonvert was the winning bidder for the Texas General Land Office's Jefferson County, Texas carbon storage lease, located in state waters offshore Beaumont and Port Arthur, Texas. The Bayou Bend CCS project site encompasses over 40,000 gross acres and, based on Talos and Carbonvert's preliminary estimates, could potentially sequester 225 to 275 million metric tons of carbon dioxide from industrial sources in the area. The Bayou Bend CCS lease is the first and only offshore lease in the U.S. dedicated to CO2 sequestration. Under the terms of the MOU, Talos and Carbonvert would contribute the Bayou Bend CCS lease to an expanded joint venture including Chevron in exchange for consideration of cash at closing and capital cost carry through the project's final investment decision. Upon closing of the joint venture, equity interests in the joint venture would be 25% Talos, 25% Carbonvert and 50% Chevron, and Talos would remain the operator. The creation of the proposed joint venture is subject to the negotiation of definitive agreements with customary closing conditions, including regulatory approval.

07:07 EDT Kymera Therapeutics announces upcoming expected milestones - IRAK4 Degrader Program: Expected 2022 Milestones: Present clinical data from patient cohort in HS and AD patients in 2H22 and Deliver data package to Sanofi for decision to proceed to Phase 2 in 2H22. STAT3 Degrader Program: Expected 2022 Milestones: Present patient data, including initial safety and proof-of-mechanism clinical data, to de-risk further development in 2H22. IRAKIMiD Degrader Program: Expected 2022 Milestones: Present patient data, including initial safety and proof-of-mechanism clinical data, to de-risk further development in 2H22. MDM2 Degrader Program: Expected 2022 Milestones: File IND for KT-253 in 2H22 and Present new preclinical data elucidating indication expansion strategies in 2H22.

07:07 EDT Estee Lauder falls over 10% to $233.50 after Q3 earnings, FY22 guidance cut

07:04 EDT Biogen to substantially eliminate commercial infrastructure for ADUHELM - Biogen issued the following Alzheimer's Disease update with its Q1 report: "In April 2022 the Centers for Medicare & Medicaid Services announced the final national coverage determination for FDA approved monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease, including ADHUELM. Due to the restrictions on coverage in the final NCD, Biogen will substantially eliminate its commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S. Biogen expects to continue funding certain regulatory and R&D activities for ADUHELM, including the continuation of the EMBARK re-dosing study and the initiation of the Phase 4 post-marketing requirement study, ENVISION. Additional actions regarding ADUHELM may be informed by upcoming data readouts expected for this class of antibodies, as well as further engagement with the FDA and CMS. The Phase 3 readout for lecanemab is expected in the fall of 2022, and Biogen is committed to working closely with Eisai on the potential launch of lecanemab."

07:03 EDT Rhythm Pharmaceuticals announces key upcoming milestones - Key Upcoming Milestones: Rhythm announced that six abstracts have been accepted for presentation at the Endocrine Society Annual Meeting & Expo, being held June 11-14, 2022 in Atlanta, GA. Dr. Jesus Argente, Universidad Autonoma de Madrid in Spain, will deliver an oral presentation of 12-month data from long-term extension trials of setmelanotide in patients with obesity due to heterozygous variants in POMC, PCSK1, and LEPR. lso in mid-2022, Rhythm anticipates announcing: Preliminary data from the ongoing Phase 2 study in patients with hypothalamic obesity; New data from the ongoing exploratory Phase 2 Basket Study evaluating setmelanotide in patients with obesity due to a variant in the MC4 receptor.

06:57 EDT OppFi names Manuel Chagas as COO - OppFi (OPFI) announced the appointments of Manuel Chagas as COO and Shaun Smolarz as Head of Investor Relations. In his role as COO, Chagas will manage OppFi's people team, operations functions, and banking partnerships to attain greater productivity as well as optimize employee and customer experiences. Prior to joining OppFi, Chagas spent eight years at Discover Financial Services (DFS) in various leadership roles, which included managing product, marketing, and operations for its student loans business.

06:55 EDT Sage Therapeutics anticipates cash and equivalents at end of FY22 of $1.3B - The Company does not anticipate receipt of any milestone payments from collaborations in 2022. The Company believes its cash and cash equivalents, anticipated funding from our ongoing collaborations, and potential revenue, will support its operations into 2025.

06:40 EDT Xenia Hotels sees FY22 capital expenditures $95M - Sees FY22 interest expense $77M.

06:30 EDT BP announces further $2.5B share buyback - During the first quarter bp generated surplus cash flow of $4.1 billion and intends to execute a $2.5 billion share buyback prior to announcing its second quarter results.

06:23 EDT Rivian to receive $1.5B incentives package to build EV factory in Georgia - Rivian will receive $1.5B in incentives to build its EV factory in Georgia, according to documents posted Monday by the state's Department of Economic Development. According to a statement: "The company will invest $5B in a carbon-conscious campus in Georgia near the I-20 corridor east of Atlanta, near Social Circle. The 7,500-job project will also include technology centers to support company research and development. Once manufacturing operations are fully ramped up, the Georgia facility will be capable of producing up to 400,000 vehicles per year." Construction is planned to begin in summer 2022, with production anticipated in 2024.

06:18 EDT Hercules Capital announces supplemental cash distribution of 15c per share - Hercules Capital is pleased to announce that its Board of Directors has declared a supplemental cash distribution of 15c per share. This supplemental cash distribution is in addition to the previously announced regular quarterly cash distribution that Hercules declared for the first quarter of 2022 of 33c per share. The record date is May 17, with payment date of May 24.

06:13 EDT NBC News says parts of 11 articles were plagiarized - NBC News on Monday said: "A review by NBC News has found 11 articles written by a reporter over the last year that did not meet our standards for original material. The articles contained passages from other news organizations that were used without attribution. In all cases, the passages were not central to the stories, but instead contained supplemental or background material that did not represent original reporting. An editor's note has been placed on each of the articles, and the passages that were plagiarized have been removed. Maintaining the trust of our readers and viewers is essential to NBC News, and our work must always meet the highest standards of our profession." NBC News is owned by Comcast through NBCUniversal. Reference Link

06:10 EDT Sonoma Pharmaceuticals, MicroSafe Group announce EPA approval of Nanocyn - Sonoma Pharmaceuticals and its partner, the MicroSafe Group DMCC, received EPA approval for Nanocyn as a hospital-grade disinfectant in the United States. Nanocyn, which is manufactured by Sonoma using its patented Microcyn Technology, is a ready to use hard-surface disinfectant that may reduce the risk of infection by treating hard, non-porous surfaces, making it especially useful in high-risk areas such as hospitals, schools, mass transit, and care facilities.

06:05 EDT Ares Commercial declares a supplemental cash dividend of 2c - The Board of Directors of the Company declared a regular cash dividend of 33c per common share and a supplemental cash dividend of 2c per common share for the Q2. The Q2 dividend and supplemental cash dividend will be payable on July 15 to common stockholders of record as of June 30.

05:24 EDT Rocket Lab announces successful launch of 26th Electron mission - Rocket Lab has successfully launched its 26th Electron mission, deploying 34 satellites to orbit. Rocket Lab has now deployed a total of 146 satellites to orbit with the Electron launch vehicle. The "There And Back Again" mission also saw Rocket Lab complete a mid-air capture of the Electron booster with a helicopter for the first time. After launching to space, Electron's first stage returned to Earth under a parachute. At 6,500 feet, Rocket Lab's Sikorsky S-92 helicopter rendezvoused with the returning stage and used a hook on a long line to capture the parachute line. The mid-air capture is a milestone in Rocket Lab's pursuit to make Electron a reusable rocket to increase launch frequency and reduce launch costs for small satellites. After the catch, the helicopter pilot detected different load characteristics than previously experienced in testing and offloaded the stage for a successful splashdown. The stage is being loaded onto Rocket Lab's recovery vessel for transport back to the company's production complex for analysis and assessment for re-flight as planned. The mid-air capture comes after successful recovery operations from Rocket Lab's 16th, 20th, and 22nd missions, which saw Electron's first stage execute a controlled ocean splashdown before being returned to Rocket Lab's production complex.

05:11 EDT SES, Sky UK extend multiple transponder contracts with SES - Sky UK extended multiple transponder contracts with SES. This renewal secures an additional contract backlog of approximately EUR 84M, building on the EUR 90M capacity agreement signed between the two companies in 2021, with contract durations up to end 2028. With this renewal, Sky UK will continue to leverage the Ku-band capacity at SES's prime neighborhood at 28.2/28.5 degrees East to deliver TV channels in standard definition, high definition and ultra-high definition to their subscribers. 28.2/28.5 degrees East is one of SES's prime TV neighborhoods reaching more than 18M TV homes in the UK and Ireland.